TY  - JOUR
AU  - Jovanović, Marija
AU  - Kovačević, Milena
AU  - Catić-Đorđević, Aleksandra
AU  - Ćulafić, Milica
AU  - Stefanović, Nikola
AU  - Mitić, Branka
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Veličković-Radovanović, Radmila
AU  - Miljković, Branislava
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4921
AB  - The study aimed to estimate and compare the prevalence and type of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) between the STOPP/START original (v1) and updated version (v2) among older patients in various settings, as well as associated factors. The study included 440 patients attending a community pharmacy, 200 outpatients and 140 nursing home users. An increase in the prevalence of STOPP v2 (57.9%) compared to v1 (56.2%) was not statistically significant in the total sample and within each setting (p>0.05). A decrease in the prevalence of START v1 (55.8%) to v2 (41.2%) was statistically significant (p<0.001) in the total sample and within each setting (p<0.05). Drug indication (32.9%) and fall-risk medications (32.2%) were most commonly identified for STOPP v2, while cardiovascular system criteria (30.5%) were the most frequently detected for START v2. The number of medications was the strongest predictor for both STOPP v1 and v2, with odds ratio values of 1.35 and 1.34, respectively. Patients’ characteristics associated with the occurrence of STOPP and START criteria were identified. According to both STOPP/START versions, the results indicate a substantial rate of potentially inappropriate prescribing among elderly patients. The prevalence of PIMs was slightly higher with the updated version, while the prevalence of PPOs was significantly lower.
T2  - Brazilian Journal of Pharmaceutical Sciences
T1  - Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria
VL  - 59
DO  - 10.1590/s2175-97902023e22549
ER  - 

@article{
author = "Jovanović, Marija and Kovačević, Milena and Catić-Đorđević, Aleksandra and Ćulafić, Milica and Stefanović, Nikola and Mitić, Branka and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Veličković-Radovanović, Radmila and Miljković, Branislava",
year = "2023",
abstract = "The study aimed to estimate and compare the prevalence and type of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) between the STOPP/START original (v1) and updated version (v2) among older patients in various settings, as well as associated factors. The study included 440 patients attending a community pharmacy, 200 outpatients and 140 nursing home users. An increase in the prevalence of STOPP v2 (57.9%) compared to v1 (56.2%) was not statistically significant in the total sample and within each setting (p>0.05). A decrease in the prevalence of START v1 (55.8%) to v2 (41.2%) was statistically significant (p<0.001) in the total sample and within each setting (p<0.05). Drug indication (32.9%) and fall-risk medications (32.2%) were most commonly identified for STOPP v2, while cardiovascular system criteria (30.5%) were the most frequently detected for START v2. The number of medications was the strongest predictor for both STOPP v1 and v2, with odds ratio values of 1.35 and 1.34, respectively. Patients’ characteristics associated with the occurrence of STOPP and START criteria were identified. According to both STOPP/START versions, the results indicate a substantial rate of potentially inappropriate prescribing among elderly patients. The prevalence of PIMs was slightly higher with the updated version, while the prevalence of PPOs was significantly lower.",
journal = "Brazilian Journal of Pharmaceutical Sciences",
title = "Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria",
volume = "59",
doi = "10.1590/s2175-97902023e22549"
}

Jovanović, M., Kovačević, M., Catić-Đorđević, A., Ćulafić, M., Stefanović, N., Mitić, B., Vučićević, K., Vezmar-Kovačević, S., Veličković-Radovanović, R.,& Miljković, B.. (2023). Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria. in Brazilian Journal of Pharmaceutical Sciences, 59.
https://doi.org/10.1590/s2175-97902023e22549

Jovanović M, Kovačević M, Catić-Đorđević A, Ćulafić M, Stefanović N, Mitić B, Vučićević K, Vezmar-Kovačević S, Veličković-Radovanović R, Miljković B. Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria. in Brazilian Journal of Pharmaceutical Sciences. 2023;59.
doi:10.1590/s2175-97902023e22549 .

Jovanović, Marija, Kovačević, Milena, Catić-Đorđević, Aleksandra, Ćulafić, Milica, Stefanović, Nikola, Mitić, Branka, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Veličković-Radovanović, Radmila, Miljković, Branislava, "Potentially inappropriate prescribing among older patients and associated factors: comparison of two versions of STOPP/START criteria" in Brazilian Journal of Pharmaceutical Sciences, 59 (2023),
https://doi.org/10.1590/s2175-97902023e22549 . .

TY  - JOUR
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Vezmar-Kovačević, Sandra
AU  - Borjanić, Slavenka
AU  - Keleč, Branka
AU  - Miljković, Branislava
AU  - Amidžić, Rada
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3973
AB  - The COVID-19 pandemic exerted a profound impact on health systems worldwide. Moreover, significant concerns were raised in terms of middle- and long-term consequences of postponing care in non-COVID patients. The primary aim of the study was to describe the remote pharmaceutical care service (telepharmacy) during the COVID-19 pandemic in the Republic of Srpska (RS), Bosnia and Herzegovina. The secondary aim was to identify service users’ needs and concerns and to describe community pharmacists’ interventions. Ten community pharmacists were appointed by the Pharmaceutical Society of the RS to deliver telepharmacy services. After obtaining users’ verbal permission, pharmacists documented issues discussed with them. The prospective data collection included the period from April 13 to May 21, 2020. Descriptive and statistical analysis was performed using IBM SPSS Statistics software (ver. 22). A total of 71 service users’ charts were analyzed. Telepharmacy users were on average 61.31 ± 13.27 years of age, with almost equal gender distribution. Patients with chronic or acute/subacute conditions were predominant with a share of 84.5%. Chronic diseases were the main reason for searching pharmacists’ consultation (74.6%), 7% had a complaint about worsening of a chronic condition, 9.9% reported only acute/subacute conditions as ambulatory conditions, whereas 15.5% asked information about coronavirus or COVID-19. The vast majority of patients’ and users’ needs were addressed by a pharmacist during counseling and only 15.5% of the patients required immediate referral to a doctor for refill/prescribing purposes. Remote pharmaceutical care service (telepharmacy) is deemed a convenient model in the RS during the COVID-19 pandemic. Patients and users presented with explicit and specific needs and concerns, both COVID- and non-COVID-related, which should not be neglected. Community pharmacists showed a high level of resilience and ability in addressing patients' needs.
PB  - John Wiley and Sons Inc
T2  - Health and Social Care in the Community
T1  - Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina
VL  - 30
IS  - 5
SP  - e1639
EP  - e1650
DO  - 10.1111/hsc.13590
ER  - 

@article{
author = "Kovačević, Milena and Ćulafić, Milica and Vezmar-Kovačević, Sandra and Borjanić, Slavenka and Keleč, Branka and Miljković, Branislava and Amidžić, Rada",
year = "2022",
abstract = "The COVID-19 pandemic exerted a profound impact on health systems worldwide. Moreover, significant concerns were raised in terms of middle- and long-term consequences of postponing care in non-COVID patients. The primary aim of the study was to describe the remote pharmaceutical care service (telepharmacy) during the COVID-19 pandemic in the Republic of Srpska (RS), Bosnia and Herzegovina. The secondary aim was to identify service users’ needs and concerns and to describe community pharmacists’ interventions. Ten community pharmacists were appointed by the Pharmaceutical Society of the RS to deliver telepharmacy services. After obtaining users’ verbal permission, pharmacists documented issues discussed with them. The prospective data collection included the period from April 13 to May 21, 2020. Descriptive and statistical analysis was performed using IBM SPSS Statistics software (ver. 22). A total of 71 service users’ charts were analyzed. Telepharmacy users were on average 61.31 ± 13.27 years of age, with almost equal gender distribution. Patients with chronic or acute/subacute conditions were predominant with a share of 84.5%. Chronic diseases were the main reason for searching pharmacists’ consultation (74.6%), 7% had a complaint about worsening of a chronic condition, 9.9% reported only acute/subacute conditions as ambulatory conditions, whereas 15.5% asked information about coronavirus or COVID-19. The vast majority of patients’ and users’ needs were addressed by a pharmacist during counseling and only 15.5% of the patients required immediate referral to a doctor for refill/prescribing purposes. Remote pharmaceutical care service (telepharmacy) is deemed a convenient model in the RS during the COVID-19 pandemic. Patients and users presented with explicit and specific needs and concerns, both COVID- and non-COVID-related, which should not be neglected. Community pharmacists showed a high level of resilience and ability in addressing patients' needs.",
publisher = "John Wiley and Sons Inc",
journal = "Health and Social Care in the Community",
title = "Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina",
volume = "30",
number = "5",
pages = "e1639-e1650",
doi = "10.1111/hsc.13590"
}

Kovačević, M., Ćulafić, M., Vezmar-Kovačević, S., Borjanić, S., Keleč, B., Miljković, B.,& Amidžić, R.. (2022). Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina. in Health and Social Care in the Community
John Wiley and Sons Inc., 30(5), e1639-e1650.
https://doi.org/10.1111/hsc.13590

Kovačević M, Ćulafić M, Vezmar-Kovačević S, Borjanić S, Keleč B, Miljković B, Amidžić R. Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina. in Health and Social Care in the Community. 2022;30(5):e1639-e1650.
doi:10.1111/hsc.13590 .

Kovačević, Milena, Ćulafić, Milica, Vezmar-Kovačević, Sandra, Borjanić, Slavenka, Keleč, Branka, Miljković, Branislava, Amidžić, Rada, "Telepharmacy service experience during the COVID-19 pandemic in the Republic of Srpska, Bosnia and Herzegovina" in Health and Social Care in the Community, 30, no. 5 (2022):e1639-e1650,
https://doi.org/10.1111/hsc.13590 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Pejić, Nina
AU  - Štulić, Miloš
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
AU  - Vučićević, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4531
AB  - Tacrolimus is an immunosuppressant used to prevent graft rejection after liver
transplantation. The narrow therapeutic range and great variability in pharmacokinetics
indicate the need for therapy individualization. The aim of the study was to develop and
validate the base pharmacokinetic model of tacrolimus using data collected during
therapeutic drug monitoring. The study included 29 liver transplant recipients followed up
at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the
NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole
blood (260). Pharmacokinetics have been described as one-compartment model with first-
order absorption and elimination. Internal validation was performed using graphical
assessment, bootstrap method and visual predictive check (VPC). Typical value of oral
clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The
value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was
best described by the exponential model, and residual by the additive model. Interindividual
variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better
agreement with the measured values than population predicted values (PRED). Conditional
weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2
standard deviations. The parameters obtained by bootstrap analysis do not deviate
significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly
were within the simulated 95% confidence interval. The obtained population
pharmacokinetic model, after additional optimization, can be used for individualization of
the tacrolimus dosing regimen in the population of liver transplant recipients.
AB  - Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - A population pharmacokinetic model of tacrolimus in adult liver transplant recipients
T1  - Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom
VL  - 72
IS  - 4 suplement
SP  - S298
EP  - S299
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4531
ER  - 

@conference{
author = "Jovanović, Marija and Ćulafić, Milica and Pejić, Nina and Štulić, Miloš and Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Ćulafić, Đorđe and Vučićević, Katarina",
year = "2022",
abstract = "Tacrolimus is an immunosuppressant used to prevent graft rejection after liver
transplantation. The narrow therapeutic range and great variability in pharmacokinetics
indicate the need for therapy individualization. The aim of the study was to develop and
validate the base pharmacokinetic model of tacrolimus using data collected during
therapeutic drug monitoring. The study included 29 liver transplant recipients followed up
at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the
NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole
blood (260). Pharmacokinetics have been described as one-compartment model with first-
order absorption and elimination. Internal validation was performed using graphical
assessment, bootstrap method and visual predictive check (VPC). Typical value of oral
clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The
value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was
best described by the exponential model, and residual by the additive model. Interindividual
variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better
agreement with the measured values than population predicted values (PRED). Conditional
weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2
standard deviations. The parameters obtained by bootstrap analysis do not deviate
significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly
were within the simulated 95% confidence interval. The obtained population
pharmacokinetic model, after additional optimization, can be used for individualization of
the tacrolimus dosing regimen in the population of liver transplant recipients., Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "A population pharmacokinetic model of tacrolimus in adult liver transplant recipients, Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom",
volume = "72",
number = "4 suplement",
pages = "S298-S299",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4531"
}

Jovanović, M., Ćulafić, M., Pejić, N., Štulić, M., Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Ćulafić, Đ.,& Vučićević, K.. (2022). A population pharmacokinetic model of tacrolimus in adult liver transplant recipients. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4531

Jovanović M, Ćulafić M, Pejić N, Štulić M, Kovačević M, Vezmar-Kovačević S, Miljković B, Ćulafić Đ, Vučićević K. A population pharmacokinetic model of tacrolimus in adult liver transplant recipients. in Arhiv za farmaciju. 2022;72(4 suplement):S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4531 .

Jovanović, Marija, Ćulafić, Milica, Pejić, Nina, Štulić, Miloš, Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Ćulafić, Đorđe, Vučićević, Katarina, "A population pharmacokinetic model of tacrolimus in adult liver transplant recipients" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S298-S299,
https://hdl.handle.net/21.15107/rcub_farfar_4531 .

TY  - CONF
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Pejić, Nina
AU  - Štulić, Miloš
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4395
AB  - Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.
AB  - Tacrolimus is an immunosuppressant used to prevent graft rejection after liver transplantation. The narrow therapeutic range and great variability in pharmacokinetics indicate the need for therapy individualization. The aim of the study was to develop and validate the base pharmacokinetic model of tacrolimus using data collected during therapeutic drug monitoring. The study included 29 liver transplant recipients followed up at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole blood (260). Pharmacokinetics have been described as one-compartment model with first- order absorption and elimination. Internal validation was performed using graphical assessment, bootstrap method and visual predictive check (VPC). Typical value of oral clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was best described by the exponential model, and residual by the additive model. Interindividual variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better agreement with the measured values than population predicted values (PRED). Conditional weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2 standard deviations. The parameters obtained by bootstrap analysis do not deviate significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly were within the simulated 95% confidence interval. The obtained population pharmacokinetic model, after additional optimization, can be used for individualization of the tacrolimus dosing regimen in the population of liver transplant recipients.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom
T1  - A population pharmacokinetic model of tacrolimus in adult liver transplant recipients
VL  - 72
IS  - 4 Suplement
SP  - S298
EP  - S299
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4395
ER  - 

@conference{
author = "Jovanović, Marija and Ćulafić, Milica and Pejić, Nina and Štulić, Miloš and Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Vučićević, Katarina and Ćulafić, Đorđe",
year = "2022",
abstract = "Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom., Tacrolimus is an immunosuppressant used to prevent graft rejection after liver transplantation. The narrow therapeutic range and great variability in pharmacokinetics indicate the need for therapy individualization. The aim of the study was to develop and validate the base pharmacokinetic model of tacrolimus using data collected during therapeutic drug monitoring. The study included 29 liver transplant recipients followed up at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole blood (260). Pharmacokinetics have been described as one-compartment model with first- order absorption and elimination. Internal validation was performed using graphical assessment, bootstrap method and visual predictive check (VPC). Typical value of oral clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was best described by the exponential model, and residual by the additive model. Interindividual variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better agreement with the measured values than population predicted values (PRED). Conditional weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2 standard deviations. The parameters obtained by bootstrap analysis do not deviate significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly were within the simulated 95% confidence interval. The obtained population pharmacokinetic model, after additional optimization, can be used for individualization of the tacrolimus dosing regimen in the population of liver transplant recipients.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom, A population pharmacokinetic model of tacrolimus in adult liver transplant recipients",
volume = "72",
number = "4 Suplement",
pages = "S298-S299",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4395"
}

Jovanović, M., Ćulafić, M., Pejić, N., Štulić, M., Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Vučićević, K.,& Ćulafić, Đ.. (2022). Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 Suplement), S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4395

Jovanović M, Ćulafić M, Pejić N, Štulić M, Kovačević M, Vezmar-Kovačević S, Miljković B, Vučićević K, Ćulafić Đ. Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom. in Arhiv za farmaciju. 2022;72(4 Suplement):S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4395 .

Jovanović, Marija, Ćulafić, Milica, Pejić, Nina, Štulić, Miloš, Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Vučićević, Katarina, Ćulafić, Đorđe, "Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom" in Arhiv za farmaciju, 72, no. 4 Suplement (2022):S298-S299,
https://hdl.handle.net/21.15107/rcub_farfar_4395 .

TY  - CONF
AU  - Marković, Aleksandra
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Jovanović, Marija
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4391
AB  - Hronična opstruktivna bolest pluća (HOBP) je oboljenje sa visokom prevalencom koje
karakteriše progresivna, ireverzibilna opstrukcija disajnih puteva često udružena sa
pojačanim inflamatornim odgovorom. Simptomi dispneje, kašlja i umora mogu negativno
uticati na kvalitet života obolelih. HOBP je često udružen sa drugim hroničnim bolestima što
doprinosi njegovom morbiditetu i mortalitetu. Cilj ovog istraživanja je procena terapije u
lečenju HOBP i pridruženih komorbiditeta. Sprovedena je opservaciona studija koja je
uključila pacijente koji su dolazili u javne apoteke da preuzmu lek na recept za lečenje HOBP.
Podaci o pacijentima su prikupljeni popunjavanjem upitnika. Deskriptivna analiza urađena je
u programu Microsoft ® Office Excel 2010. U istraživanje je uključeno 82 ispitanika, od kojih
su brojniji bili muškarci (56,1%). Prosečna starost ispitanika iznosila je 66,1±10,6, sa
prosečnim trajanjem bolesti 10,2±3,8 godina. Najveći broj (89%) primenjivao je
kombinovane inhalacione preparate (antiholinergik+β-agonista), antiholinergik 46,3%,
salbutamol 24,4%, teofilin/aminofilin 26,9%, inhalacioni kortikosteroid 11.0%, antibiotike
14,6% i oralne kortikosteroide 4,9%. Čak 97,6% pacijenata imao je pridruženu hroničnu
bolest - broj komorbiditeta po pacijentu 1-5. U 73,8% slučajeva je u pitanju hipertenzija,
21,3% imalo je astmu, i 12,2% dijabetes ili srčanu slabost. Primenom mMRC (modified
Medical Research Council) skale za procenu dispneje, vrednosti ≥2 imalo je 53,7% ispitanika
što ukazuje na slabo kontrolisanu bolest. Skoro četvrtina pacijenata bila je hospitalizovana
zbog egzacerbacije (23,2%), 53,7% vakcinisano protiv gripa, a samo 3,7% protiv
pneumokoka. Oko trećina ispitanika bili su pušači (35,4%). Uzimajući u obzir zastupljenost
komorbiditeta u ovoj populaciji i složenost terapije, savetovanje i praćenje od strane
farmaceuta moglo bi značajno doprineti sprečavanju potencijalnih terapijskih problema.
AB  - Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease
characterized by progressive, irreversible airway obstruction often associated with
increased inflammatory response. Symptoms including dyspnea, cough and fatigue can
negatively affect patients’ quality of life. COPD is often associated with other chronic diseases
that contribute to its morbidity and mortality. The aim of this research was to evaluate the
therapy of COPD and comorbidities. An observational study included patients with a
prescription for COPD medications. Patients’ data were collected by completing
questionnaires in the community pharmacies. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Among 82 participants most of them were men (56.1%).
Participants’ average age was 66.1±10.6 with an average disease duration of 10.2±3.8 years.
Most participants (89%) used combined inhalation preparations (anticholinergic+β-agonist),
anticholinergic 46.3%, salbutamol 24.4%, theophylline/aminophylline 26.9%, inhaled
corticosteroid 11.0%, antibiotics 14.6% and oral corticosteroids 4.9%. Additional chronic
disease was present in 97.6% of patients, with 1-5 comorbidities per patient. The majority of
patients also had hypertension 73.8%, 21.3% asthma and 12.2% diabetes or heart failure.
Using the mMRC (modified Medical Research Council) scale for the assessment of dyspnea,
53.7% had a score ≥2, indicating a poorly controlled disease. Almost a quarter of patients
were hospitalized for exacerbation (23.2%), 53.7% were vaccinated against influenza, only
3.7% against pneumococcus and about a third were smokers (35.4%). Given the prevalence
of comorbidities in this population and the complexity of therapy, counseling and monitoring
by pharmacists could make a significant contribution to preventing potential drug-related
problems.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća
T1  - Assessment of therapy and comorbidities in patients with chronic obstructive pulmonary disease
VL  - 72
IS  - 4-suplement
SP  - S282
EP  - S283
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4391
ER  - 

@conference{
author = "Marković, Aleksandra and Kovačević, Milena and Ćulafić, Milica and Roganović, Maša and Jovanović, Marija and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Hronična opstruktivna bolest pluća (HOBP) je oboljenje sa visokom prevalencom koje
karakteriše progresivna, ireverzibilna opstrukcija disajnih puteva često udružena sa
pojačanim inflamatornim odgovorom. Simptomi dispneje, kašlja i umora mogu negativno
uticati na kvalitet života obolelih. HOBP je često udružen sa drugim hroničnim bolestima što
doprinosi njegovom morbiditetu i mortalitetu. Cilj ovog istraživanja je procena terapije u
lečenju HOBP i pridruženih komorbiditeta. Sprovedena je opservaciona studija koja je
uključila pacijente koji su dolazili u javne apoteke da preuzmu lek na recept za lečenje HOBP.
Podaci o pacijentima su prikupljeni popunjavanjem upitnika. Deskriptivna analiza urađena je
u programu Microsoft ® Office Excel 2010. U istraživanje je uključeno 82 ispitanika, od kojih
su brojniji bili muškarci (56,1%). Prosečna starost ispitanika iznosila je 66,1±10,6, sa
prosečnim trajanjem bolesti 10,2±3,8 godina. Najveći broj (89%) primenjivao je
kombinovane inhalacione preparate (antiholinergik+β-agonista), antiholinergik 46,3%,
salbutamol 24,4%, teofilin/aminofilin 26,9%, inhalacioni kortikosteroid 11.0%, antibiotike
14,6% i oralne kortikosteroide 4,9%. Čak 97,6% pacijenata imao je pridruženu hroničnu
bolest - broj komorbiditeta po pacijentu 1-5. U 73,8% slučajeva je u pitanju hipertenzija,
21,3% imalo je astmu, i 12,2% dijabetes ili srčanu slabost. Primenom mMRC (modified
Medical Research Council) skale za procenu dispneje, vrednosti ≥2 imalo je 53,7% ispitanika
što ukazuje na slabo kontrolisanu bolest. Skoro četvrtina pacijenata bila je hospitalizovana
zbog egzacerbacije (23,2%), 53,7% vakcinisano protiv gripa, a samo 3,7% protiv
pneumokoka. Oko trećina ispitanika bili su pušači (35,4%). Uzimajući u obzir zastupljenost
komorbiditeta u ovoj populaciji i složenost terapije, savetovanje i praćenje od strane
farmaceuta moglo bi značajno doprineti sprečavanju potencijalnih terapijskih problema., Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease
characterized by progressive, irreversible airway obstruction often associated with
increased inflammatory response. Symptoms including dyspnea, cough and fatigue can
negatively affect patients’ quality of life. COPD is often associated with other chronic diseases
that contribute to its morbidity and mortality. The aim of this research was to evaluate the
therapy of COPD and comorbidities. An observational study included patients with a
prescription for COPD medications. Patients’ data were collected by completing
questionnaires in the community pharmacies. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Among 82 participants most of them were men (56.1%).
Participants’ average age was 66.1±10.6 with an average disease duration of 10.2±3.8 years.
Most participants (89%) used combined inhalation preparations (anticholinergic+β-agonist),
anticholinergic 46.3%, salbutamol 24.4%, theophylline/aminophylline 26.9%, inhaled
corticosteroid 11.0%, antibiotics 14.6% and oral corticosteroids 4.9%. Additional chronic
disease was present in 97.6% of patients, with 1-5 comorbidities per patient. The majority of
patients also had hypertension 73.8%, 21.3% asthma and 12.2% diabetes or heart failure.
Using the mMRC (modified Medical Research Council) scale for the assessment of dyspnea,
53.7% had a score ≥2, indicating a poorly controlled disease. Almost a quarter of patients
were hospitalized for exacerbation (23.2%), 53.7% were vaccinated against influenza, only
3.7% against pneumococcus and about a third were smokers (35.4%). Given the prevalence
of comorbidities in this population and the complexity of therapy, counseling and monitoring
by pharmacists could make a significant contribution to preventing potential drug-related
problems.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća, Assessment of therapy and comorbidities in patients with chronic obstructive pulmonary disease",
volume = "72",
number = "4-suplement",
pages = "S282-S283",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4391"
}

Marković, A., Kovačević, M., Ćulafić, M., Roganović, M., Jovanović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S282-S283.
https://hdl.handle.net/21.15107/rcub_farfar_4391

Marković A, Kovačević M, Ćulafić M, Roganović M, Jovanović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća. in Arhiv za farmaciju. 2022;72(4-suplement):S282-S283.
https://hdl.handle.net/21.15107/rcub_farfar_4391 .

Marković, Aleksandra, Kovačević, Milena, Ćulafić, Milica, Roganović, Maša, Jovanović, Marija, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Procena terapije i komorbiditeta kod pacijenata sa hroničnom opstruktivnom bolešću pluća" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S282-S283,
https://hdl.handle.net/21.15107/rcub_farfar_4391 .

TY  - CONF
AU  - Lazarević, Katarina
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4390
AB  - Astma predstavlja veliko globalno opterećenje jer se uprkos dostupnoj terapiji beleže
loši zdravstveni i socio-ekonomski ishodi. Cilj ovog rada je analiza primenjene terapije i
koterapije kod pacijenata obolelih od astme i identifikacija terapijskih problema. Sprovedena
opservaciona studija je uključila 57 odraslih pacijenata sa astmom, oba pola. Podaci su
prikupljani tokom 2016. godine u javnim apotekama, popunjavanjem upitnika. Deskriptivna
analiza je izvršena u programu Microsoft ® Office Excel 2010. Prosečna starost iznosila je
49,7±17,4 godina, 38,6% činili su muškarci. Kratkodelujuće beta-2 agoniste primenjivalo je
36,8% pacijenata, dugodelujuće beta-2 agoniste 8,8%, inhalacione kortikosteroide 28,1%,
dok je kombinovane preparate upotrebljavalo 73,7%. Više od 50% koristilo je inhalacione
antiholinergike, a primećena je upotreba teofilina/aminofilina kod 31,6%, što nije u
saglasnosti sa smernicama za terapiju astme usled slabe efikasnosti, odnosno lošeg
bezbednosnog profila. Takođe, ovaj rezultat može ukazati na to da pacijenti ne prihvataju
inhalacionu terapiju zbog zahtevnijeg načina primene ili zbog više cene lekova. Od
pridruženih komorbiditeta, najčešći su bili alergijski rinitis, gojaznost, hipertenzija i
gastroezofagealna refluksna bolest. Potencijalno neadekvatna koterapija uključivala je beta-
blokatore (21,1%), inhibitore angiotenzin-konvertujućeg enzima (28,1%), acetilsalicilnu
kiselinu/nesteroidne antiinflamatorne lekove (21,1% i 29,8%) čija primena može
precipitirati pogoršanje astme. Obeshrabrujuće je da su 26,3% pacijenata pušači, 35,1% ne
zna koji su okidači za njihovu bolest, a samo 1 pacijent koristi astma akcioni plan. Rezultati
ukazuju na veću zastupljenost terapije koja odgovara težim stadijumima astme, što može
ukazivati na lošiju kontrolu bolesti i lošije ishode. Uočava se potreba za uvođenjem usluga
farmaceutske zdravstvene zaštite i boljom edukacijom pacijenata o astmi.
AB  - Asthma represents a serious global burden because, despite available therapy, poor
health and socio-economic outcomes are reported. The aim of this paper is to analyse
treatment in patients with asthma and to identify drug-related problems. An observational
study included 57 adult asthma patients of both genders. Data were collected in community
pharmacies during 2016, by filling out questionnaires. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Respondents’ average age was 49.7±17.4, 38.6% were men.
Patients used short-acting (36.8%) and long-acting beta-2 agonists (8.8%), inhaled
corticosteroids (28.1%) and combined preparations (73.7%). More than 50% of patients
used inhaled anticholinergics, while theophylline was used in 31.6%, which is in discordance
with the asthma guidelines, due to poor efficacy and safety profile. Also, this may indicate
that patients do not accept inhalation therapy because of demanding technique or higher
cost. Allergic rhinitis, obesity, hypertension, and gastroesophageal reflux disease were the
most common comorbidities. Potentially inadequate co-therapy included beta-blockers
(21.1%), angiotensin-converting enzyme inhibitors (28.1%), aspirin/nonsteroidal
antiinflamatory drugs (21.1% and 29.8%), which may worsen asthma. It is discouraging that
26.3% of patients were smokers, 35.1% did not know the triggers for asthma, and only 1
patient used the asthma action plan. The results show a higher prevalence of therapy
appropriate for severe asthma stages, which implies poor disease control and poor
outcomes. There is a need for the implementation of pharmaceutical care services and better
education of patients with asthma.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti
T1  - Review of therapy and therapeutic problems in patients with asthma in primary health care
VL  - 72
IS  - 4-suplement
SP  - S280
EP  - S281
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4390
ER  - 

@conference{
author = "Lazarević, Katarina and Kovačević, Milena and Ćulafić, Milica and Jovanović, Marija and Roganović, Maša and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Astma predstavlja veliko globalno opterećenje jer se uprkos dostupnoj terapiji beleže
loši zdravstveni i socio-ekonomski ishodi. Cilj ovog rada je analiza primenjene terapije i
koterapije kod pacijenata obolelih od astme i identifikacija terapijskih problema. Sprovedena
opservaciona studija je uključila 57 odraslih pacijenata sa astmom, oba pola. Podaci su
prikupljani tokom 2016. godine u javnim apotekama, popunjavanjem upitnika. Deskriptivna
analiza je izvršena u programu Microsoft ® Office Excel 2010. Prosečna starost iznosila je
49,7±17,4 godina, 38,6% činili su muškarci. Kratkodelujuće beta-2 agoniste primenjivalo je
36,8% pacijenata, dugodelujuće beta-2 agoniste 8,8%, inhalacione kortikosteroide 28,1%,
dok je kombinovane preparate upotrebljavalo 73,7%. Više od 50% koristilo je inhalacione
antiholinergike, a primećena je upotreba teofilina/aminofilina kod 31,6%, što nije u
saglasnosti sa smernicama za terapiju astme usled slabe efikasnosti, odnosno lošeg
bezbednosnog profila. Takođe, ovaj rezultat može ukazati na to da pacijenti ne prihvataju
inhalacionu terapiju zbog zahtevnijeg načina primene ili zbog više cene lekova. Od
pridruženih komorbiditeta, najčešći su bili alergijski rinitis, gojaznost, hipertenzija i
gastroezofagealna refluksna bolest. Potencijalno neadekvatna koterapija uključivala je beta-
blokatore (21,1%), inhibitore angiotenzin-konvertujućeg enzima (28,1%), acetilsalicilnu
kiselinu/nesteroidne antiinflamatorne lekove (21,1% i 29,8%) čija primena može
precipitirati pogoršanje astme. Obeshrabrujuće je da su 26,3% pacijenata pušači, 35,1% ne
zna koji su okidači za njihovu bolest, a samo 1 pacijent koristi astma akcioni plan. Rezultati
ukazuju na veću zastupljenost terapije koja odgovara težim stadijumima astme, što može
ukazivati na lošiju kontrolu bolesti i lošije ishode. Uočava se potreba za uvođenjem usluga
farmaceutske zdravstvene zaštite i boljom edukacijom pacijenata o astmi., Asthma represents a serious global burden because, despite available therapy, poor
health and socio-economic outcomes are reported. The aim of this paper is to analyse
treatment in patients with asthma and to identify drug-related problems. An observational
study included 57 adult asthma patients of both genders. Data were collected in community
pharmacies during 2016, by filling out questionnaires. Descriptive analysis was performed in
Microsoft® Office Excel 2010. Respondents’ average age was 49.7±17.4, 38.6% were men.
Patients used short-acting (36.8%) and long-acting beta-2 agonists (8.8%), inhaled
corticosteroids (28.1%) and combined preparations (73.7%). More than 50% of patients
used inhaled anticholinergics, while theophylline was used in 31.6%, which is in discordance
with the asthma guidelines, due to poor efficacy and safety profile. Also, this may indicate
that patients do not accept inhalation therapy because of demanding technique or higher
cost. Allergic rhinitis, obesity, hypertension, and gastroesophageal reflux disease were the
most common comorbidities. Potentially inadequate co-therapy included beta-blockers
(21.1%), angiotensin-converting enzyme inhibitors (28.1%), aspirin/nonsteroidal
antiinflamatory drugs (21.1% and 29.8%), which may worsen asthma. It is discouraging that
26.3% of patients were smokers, 35.1% did not know the triggers for asthma, and only 1
patient used the asthma action plan. The results show a higher prevalence of therapy
appropriate for severe asthma stages, which implies poor disease control and poor
outcomes. There is a need for the implementation of pharmaceutical care services and better
education of patients with asthma.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti, Review of therapy and therapeutic problems in patients with asthma in primary health care",
volume = "72",
number = "4-suplement",
pages = "S280-S281",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4390"
}

Lazarević, K., Kovačević, M., Ćulafić, M., Jovanović, M., Roganović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S280-S281.
https://hdl.handle.net/21.15107/rcub_farfar_4390

Lazarević K, Kovačević M, Ćulafić M, Jovanović M, Roganović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4-suplement):S280-S281.
https://hdl.handle.net/21.15107/rcub_farfar_4390 .

Lazarević, Katarina, Kovačević, Milena, Ćulafić, Milica, Jovanović, Marija, Roganović, Maša, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Pregled terapije i terapijskih problema kod pacijenata sa astmom u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S280-S281,
https://hdl.handle.net/21.15107/rcub_farfar_4390 .

TY  - CONF
AU  - Lazarević, Katarina
AU  - Marković, Aleksandra
AU  - Vezmar-Kovačević, Sandra
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4389
AB  - Benigna hiperplazija prostate (BHP) predstavlja nekancerozno uvećanje prostate
povezano sa simptomima donjeg urinarnog trakta i spada u najčešća oboljenja starijih
muškaraca. Kako su u ovom dobu uobičajeni komorbiditeti, pre svega kardiovaskularna
(KVS) oboljenja, može se očekivati veliki broj klinički značajnih interakcija lekova. Svrha ove
studije bila je analiza učestalosti i vrste potencijalnih interakcija u terapiji starijih pacijenata
sa BHP i KVS oboljenjem. Sprovedeno retrospektivno istraživanje uključilo je 93 muškaraca
starijih od 65 godina, obolelih od BHP i hipertenzije ili nekog KVS oboljenja. Podaci o
pacijentima su prikupljani iz medicinske dokumentacije. Potencijalne interakcije su
identifikovane i procenjivane korišćenjem Lexicomp® elektronske baze podataka.
Deskriptivna analiza je obavljena u programu Microsoft ® Office Excel 2010. Prosečna starost
ispitanika iznosila je 75,3±6,05. Broj lekova u terapiji bio je u rasponu od 2 do 13. Pet ili više
lekova primenjivalo je 72,04% pacijenata. Detektovano je ukupno 509 interakcija, od kojih
čak 467 spada u klinički značajne (C, D, X). Najveći broj identifikovanih interakcija pripada
klasi C (85,46%), dok je 4,91% iz klase D, a samo 1,38% iz klase X. U okviru klase X, koja
ukazuje da treba izbegavati istovremenu primenu kombinacije lekova, najčešće se javljala
interakcija između dva α-blokatora. Zabeleženo je 412 farmakodinamskih i 47
farmakokinetičkih interakcija. Dvojni mehanizam je detektovan kod 29 interakcija, a 21 se
odvijao nepoznatim mehanizmom. Rezultati studije upućuju da uključivanje farmaceuta u
praćenje pacijenata sa BHP može biti korisno, imajući u vidu značajan broj identifikovanih
klinički značajnih interakcija.
AB  - Benign prostatic hyperplasia (BPH) represents a non-cancerous prostate enlargement
associated with lower urinary tract symptoms and is one of the most common diseases in
older men. As comorbidities, primarily cardiovascular diseases (CVD) are common in this
age group, a great number of clinically significant drug interactions can be expected. The aim
of this research was to estimate the frequency and type of potential interactions in the
treatment of elderly with BPH and CVD. A retrospective study included 93 men aged over 65
with BPH and hypertension or CVD. Patients’ data were collected from medical records.
Potential interactions were identified and assessed using the Lexicomp ® database.
Descriptive analysis was performed in Microsoft® Office Excel 2010. Patients’ average age
was 75.3±6.05. The number of drugs in therapy ranged from 2 to 13. Five or more drugs
were used by 72.04% of the patients. A total of 509 interactions were detected, of which 467
are clinically significant (C, D, X). Most interactions belonged to category C (85.46%), while
4.91% belonged to class D, and only 1.38% to class X. Within class X, which indicates that
concomitant use of drugs should be avoided, the interaction between the two α-blockers was
most frequent. 412 pharmacodynamic and 47 pharmacokinetic interactions were identified.
The dual mechanism was detected in 29 interactions, while for 21 the mechanism was
unknown. The obtained results suggest the involvement of pharmacists in the monitoring of
patients with BPH may be useful, given the great proportion of identified clinically significant
interactions.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima
T1  - Monitoring of drug interactions in elderly patients with benign prostatic hyperplasia and cardiovascular diseases
VL  - 72
IS  - 4-suplement
SP  - S278
EP  - S279
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4389
ER  - 

@conference{
author = "Lazarević, Katarina and Marković, Aleksandra and Vezmar-Kovačević, Sandra and Jovanović, Marija and Ćulafić, Milica and Kovačević, Milena and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Benigna hiperplazija prostate (BHP) predstavlja nekancerozno uvećanje prostate
povezano sa simptomima donjeg urinarnog trakta i spada u najčešća oboljenja starijih
muškaraca. Kako su u ovom dobu uobičajeni komorbiditeti, pre svega kardiovaskularna
(KVS) oboljenja, može se očekivati veliki broj klinički značajnih interakcija lekova. Svrha ove
studije bila je analiza učestalosti i vrste potencijalnih interakcija u terapiji starijih pacijenata
sa BHP i KVS oboljenjem. Sprovedeno retrospektivno istraživanje uključilo je 93 muškaraca
starijih od 65 godina, obolelih od BHP i hipertenzije ili nekog KVS oboljenja. Podaci o
pacijentima su prikupljani iz medicinske dokumentacije. Potencijalne interakcije su
identifikovane i procenjivane korišćenjem Lexicomp® elektronske baze podataka.
Deskriptivna analiza je obavljena u programu Microsoft ® Office Excel 2010. Prosečna starost
ispitanika iznosila je 75,3±6,05. Broj lekova u terapiji bio je u rasponu od 2 do 13. Pet ili više
lekova primenjivalo je 72,04% pacijenata. Detektovano je ukupno 509 interakcija, od kojih
čak 467 spada u klinički značajne (C, D, X). Najveći broj identifikovanih interakcija pripada
klasi C (85,46%), dok je 4,91% iz klase D, a samo 1,38% iz klase X. U okviru klase X, koja
ukazuje da treba izbegavati istovremenu primenu kombinacije lekova, najčešće se javljala
interakcija između dva α-blokatora. Zabeleženo je 412 farmakodinamskih i 47
farmakokinetičkih interakcija. Dvojni mehanizam je detektovan kod 29 interakcija, a 21 se
odvijao nepoznatim mehanizmom. Rezultati studije upućuju da uključivanje farmaceuta u
praćenje pacijenata sa BHP može biti korisno, imajući u vidu značajan broj identifikovanih
klinički značajnih interakcija., Benign prostatic hyperplasia (BPH) represents a non-cancerous prostate enlargement
associated with lower urinary tract symptoms and is one of the most common diseases in
older men. As comorbidities, primarily cardiovascular diseases (CVD) are common in this
age group, a great number of clinically significant drug interactions can be expected. The aim
of this research was to estimate the frequency and type of potential interactions in the
treatment of elderly with BPH and CVD. A retrospective study included 93 men aged over 65
with BPH and hypertension or CVD. Patients’ data were collected from medical records.
Potential interactions were identified and assessed using the Lexicomp ® database.
Descriptive analysis was performed in Microsoft® Office Excel 2010. Patients’ average age
was 75.3±6.05. The number of drugs in therapy ranged from 2 to 13. Five or more drugs
were used by 72.04% of the patients. A total of 509 interactions were detected, of which 467
are clinically significant (C, D, X). Most interactions belonged to category C (85.46%), while
4.91% belonged to class D, and only 1.38% to class X. Within class X, which indicates that
concomitant use of drugs should be avoided, the interaction between the two α-blockers was
most frequent. 412 pharmacodynamic and 47 pharmacokinetic interactions were identified.
The dual mechanism was detected in 29 interactions, while for 21 the mechanism was
unknown. The obtained results suggest the involvement of pharmacists in the monitoring of
patients with BPH may be useful, given the great proportion of identified clinically significant
interactions.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima, Monitoring of drug interactions in elderly patients with benign prostatic hyperplasia and cardiovascular diseases",
volume = "72",
number = "4-suplement",
pages = "S278-S279",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4389"
}

Lazarević, K., Marković, A., Vezmar-Kovačević, S., Jovanović, M., Ćulafić, M., Kovačević, M., Vučićević, K.,& Miljković, B.. (2022). Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S278-S279.
https://hdl.handle.net/21.15107/rcub_farfar_4389

Lazarević K, Marković A, Vezmar-Kovačević S, Jovanović M, Ćulafić M, Kovačević M, Vučićević K, Miljković B. Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima. in Arhiv za farmaciju. 2022;72(4-suplement):S278-S279.
https://hdl.handle.net/21.15107/rcub_farfar_4389 .

Lazarević, Katarina, Marković, Aleksandra, Vezmar-Kovačević, Sandra, Jovanović, Marija, Ćulafić, Milica, Kovačević, Milena, Vučićević, Katarina, Miljković, Branislava, "Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S278-S279,
https://hdl.handle.net/21.15107/rcub_farfar_4389 .

TY  - CONF
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Milenković, Branislava
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4388
AB  - Lečenje astme i hronične opstruktivne bolesti pluća (HOBP) zahteva optimalnu
upotrebu inhalatora. Farmaceuti imaju značajnu ulogu u edukaciji pacijenata o pravilnoj
upotrebi inhalatora, uključujuć i inhalatore za suvi prašak (eng. Dry Powder Inhalers, DPI). Cilj
studije je bio da se procene i uporede veštine demonstracije farmaceuta za DPI pre i posle
edukacije. U studiju su uključeni samo farmaceuti bez prethodne obuke za pravilnu upotrebu
inhalatora. Skor farmaceuta je procenjen na početku i nakon obuke za pravilnu upotrebu 5
tipova DPI. Učesnici su dobijali 1 poen za svaki od četiri pravilno izvedenih koraka.
Statistička analiza je izvršena korišćenjem SPSS programa (verzija 25). Wilcoxon test je
korišćen za poređenje rezultata pre i posle edukacije. Prosečan skor nakon obuke bio je
3,8±0,57 za sve tipove DPI. Uočena je statistički značajna razlika (p<0,05) u postignutim
skorovama pre i posle obuke farmaceuta uzimajući u obzir 594 poređenja. U 575 slučajeva
skor je bio viši nakon obuke, u samo 2 slučaja skor je bio niži, dok je u 17 slučajeva bio
izjednačen. Ukupna stopa greške za prvi korak (priprema uređaja) bila je 2,86%, za drugi
korak (izdisaj) 4,71%, za treć i korak (udisaj) 6,73% i za poslednji korak (zadržavanje daha)
5,56%. Rezultati ukazuju da je obuka unapredila veštine farmaceuta u vezi sa tehnikom
primene DPI. To može doprineti boljoj kontroli astme i HOBP, nakon edukacije pacijenata.
Ovo je posebno važno imajući u vidu da su farmaceuti najpristupačniji zdravstveni radnici.
AB  - Treatment of asthma and chronic obstructive pulmonary disease (COPD) requires
optimal use of inhalers. Pharmacists have a significant role in educating patients on the
correct use of inhalers, including dry powder inhalers (DPI). The aim of the study was to
assess and compare pharmacists’ DPI technique demonstration skills before and after the
education. The study included only pharmacists without previous training for correct use of
inhalers. Pharmacists’ score was assessed at baseline and after the training of the correct use
of 5 types of DPI. The participants were given a 1-point score for each of four steps
performed correctly. Statistical analysis was performed using the SPSS program (version
25). Wilcoxon test was used for score comparison before and after education. The mean
score after training was 3.8±0.57 for all types of DPI. There was a statistically significant
difference (p<0.05) in achieved scores before and after pharmacists' training taking into
account 594 comparisons. In 575 cases the score was higher after training, in only 2 cases
the score was lower, while in 17 cases it was even. The total error rate for first step (device
preparation) was 2.86%, for second step (expiration) it was 4.71%, for third step
(inhalation) it was 6.73% and for last step (holding breath) it was 5.56%. The results imply
that training improved pharmacist skills regarding the DPI technique. It may contribute to
better control of asthma and COPD, after education of patients. This is especially important
considering that pharmacist are the most accessible health care professionals.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak
T1  - Evaluation of inhalation technique of community pharmacists - focus on dry powder inhalers
VL  - 72
IS  - 4-suplement
SP  - S274
EP  - S275
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4388
ER  - 

@conference{
author = "Jovanović, Marija and Roganović, Maša and Kovačević, Milena and Ćulafić, Milica and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Milenković, Branislava and Miljković, Branislava",
year = "2022",
abstract = "Lečenje astme i hronične opstruktivne bolesti pluća (HOBP) zahteva optimalnu
upotrebu inhalatora. Farmaceuti imaju značajnu ulogu u edukaciji pacijenata o pravilnoj
upotrebi inhalatora, uključujuć i inhalatore za suvi prašak (eng. Dry Powder Inhalers, DPI). Cilj
studije je bio da se procene i uporede veštine demonstracije farmaceuta za DPI pre i posle
edukacije. U studiju su uključeni samo farmaceuti bez prethodne obuke za pravilnu upotrebu
inhalatora. Skor farmaceuta je procenjen na početku i nakon obuke za pravilnu upotrebu 5
tipova DPI. Učesnici su dobijali 1 poen za svaki od četiri pravilno izvedenih koraka.
Statistička analiza je izvršena korišćenjem SPSS programa (verzija 25). Wilcoxon test je
korišćen za poređenje rezultata pre i posle edukacije. Prosečan skor nakon obuke bio je
3,8±0,57 za sve tipove DPI. Uočena je statistički značajna razlika (p<0,05) u postignutim
skorovama pre i posle obuke farmaceuta uzimajući u obzir 594 poređenja. U 575 slučajeva
skor je bio viši nakon obuke, u samo 2 slučaja skor je bio niži, dok je u 17 slučajeva bio
izjednačen. Ukupna stopa greške za prvi korak (priprema uređaja) bila je 2,86%, za drugi
korak (izdisaj) 4,71%, za treć i korak (udisaj) 6,73% i za poslednji korak (zadržavanje daha)
5,56%. Rezultati ukazuju da je obuka unapredila veštine farmaceuta u vezi sa tehnikom
primene DPI. To može doprineti boljoj kontroli astme i HOBP, nakon edukacije pacijenata.
Ovo je posebno važno imajući u vidu da su farmaceuti najpristupačniji zdravstveni radnici., Treatment of asthma and chronic obstructive pulmonary disease (COPD) requires
optimal use of inhalers. Pharmacists have a significant role in educating patients on the
correct use of inhalers, including dry powder inhalers (DPI). The aim of the study was to
assess and compare pharmacists’ DPI technique demonstration skills before and after the
education. The study included only pharmacists without previous training for correct use of
inhalers. Pharmacists’ score was assessed at baseline and after the training of the correct use
of 5 types of DPI. The participants were given a 1-point score for each of four steps
performed correctly. Statistical analysis was performed using the SPSS program (version
25). Wilcoxon test was used for score comparison before and after education. The mean
score after training was 3.8±0.57 for all types of DPI. There was a statistically significant
difference (p<0.05) in achieved scores before and after pharmacists' training taking into
account 594 comparisons. In 575 cases the score was higher after training, in only 2 cases
the score was lower, while in 17 cases it was even. The total error rate for first step (device
preparation) was 2.86%, for second step (expiration) it was 4.71%, for third step
(inhalation) it was 6.73% and for last step (holding breath) it was 5.56%. The results imply
that training improved pharmacist skills regarding the DPI technique. It may contribute to
better control of asthma and COPD, after education of patients. This is especially important
considering that pharmacist are the most accessible health care professionals.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak, Evaluation of inhalation technique of community pharmacists - focus on dry powder inhalers",
volume = "72",
number = "4-suplement",
pages = "S274-S275",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4388"
}

Jovanović, M., Roganović, M., Kovačević, M., Ćulafić, M., Vučićević, K., Vezmar-Kovačević, S., Milenković, B.,& Miljković, B.. (2022). Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S274-S275.
https://hdl.handle.net/21.15107/rcub_farfar_4388

Jovanović M, Roganović M, Kovačević M, Ćulafić M, Vučićević K, Vezmar-Kovačević S, Milenković B, Miljković B. Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak. in Arhiv za farmaciju. 2022;72(4-suplement):S274-S275.
https://hdl.handle.net/21.15107/rcub_farfar_4388 .

Jovanović, Marija, Roganović, Maša, Kovačević, Milena, Ćulafić, Milica, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Milenković, Branislava, Miljković, Branislava, "Procena tehnike inhalacije farmaceuta u primarnoj zdravstvenoj zaštiti ‐ fokus na inhalatore za suvi prašak" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S274-S275,
https://hdl.handle.net/21.15107/rcub_farfar_4388 .

TY  - CONF
AU  - Homšek, Ana
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4387
AB  - Kako glavobolje predstavljaju jedno od najčešćih onesposobljavajućih stanja u svetu, 1
a mogu se lečiti lekovima koji se izdaju bez recepta, uloga farmaceuta u zbrinjavanju ovih
pacijenata prepoznata je kao veoma značajna. Cilj istraživanja bio je da se ispitaju percepcije
farmaceuta u primarnoj zdravstvenoj zaštiti o pružanju usluge pacijentima, kao i o
sprovedenoj edukaciji specijalizovanoj ka glavoboljama. Podaci su prikupljani putem ankete,
prilagođene prema prethodnom radu2 i obrađeni u programima SPSS i Microsoft Excel.
Popunjavanju ankete pristupilo je 43 farmaceuta iz primarne zdravstvene zaštite (90,7%
žene, raspon godina 27-64). Provera pouzdanosti ankete potvrđena je upotrebom Cronbach-
ovog testa (αB = 0,727; αC = 0,880). Najveći broj anketiranih farmaceuta smatra da pažljivo
sluša pacijente sa glavoboljom (65% uvek, 27,9% često), interakcije uvek proverava čak
44,7%, dok o pravilnoj primeni leka njih 86,04% uvek posavetuje pacijenta. Međutim,
34,88% prijavljuje da nikada ne kontaktira lekare ukoliko je lek skup, ne refundira se ili
izaziva neželjenu reakciju koja ograničava primenu, a 32,55% samo ponekad to učini. Većina
farmaceuta smatra da je edukacija korisna za bolje razumevanje pacijenata i savetovanje o
glavoboljama (97,67-100%), dok nešto manji procenat (93,02%) smatra da je edukacija
korisna da lakše prepoznaju pacijenta sa migrenom i upute ga lekaru. Percepcija većine
farmaceuta je da savetuje pacijente o terapiji glavobolje i bez prethodne edukacije, ali da bi
uz edukaciju usluga koju pružaju bila kompletnija. Rezultati studije upućuju da buduće
edukacije treba fokusirati na unapređenje komunikacije sa lekarima.
AB  - Since headaches represent one of the most common disabling conditions in the world1
and can be treated with over-the-counter drugs, the role of pharmacists in caring for these
patients has been recognized as very important. The research aim was to review primary
health care pharmacists’ perception regarding patient service they provide and the
conducted education devoted to headaches. Data were collected through a survey adapted
from the published article 2 and analysed in SPSS and Microsoft Excel. The survey was
completed by 43 primary health care pharmacists (90.7% women, age 27-64). The survey
reliability was verified using the Cronbach’s test (αB = 0.727; αC = 0.880). Most of the
surveyed pharmacists believe that they listen carefully to patients with headaches (65%
always, 27.9% often), 44.7% always check interactions, while 86.04% always advise the
patient on proper drug administration. However, 34.88% report that they never contact
doctors if the drug is expensive, not reimbursable or causes an adverse reaction that limits
its use, and 32.55% only sometimes do so. Most pharmacists believe education was useful to
better understand patients and counsel them about headaches (97.67-100%), while a
slightly smaller percentage (93.02%) thinks it helped them learn to identify a migraine
patient and refer him to a doctor. The perception of most pharmacists is that they advise
patients on headache treatment even without prior education, but after it, the service would
be more complete. The study results indicate that future education should focus on
improving communication with doctors.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti
T1  - Pharmacists’ perception about providing services to patients with headaches in primary care
VL  - 72
IS  - 4 suplement
SP  - S264
EP  - S265
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4387
ER  - 

@conference{
author = "Homšek, Ana and Jovanović, Marija and Roganović, Maša and Kovačević, Milena and Ćulafić, Milica and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Kako glavobolje predstavljaju jedno od najčešćih onesposobljavajućih stanja u svetu, 1
a mogu se lečiti lekovima koji se izdaju bez recepta, uloga farmaceuta u zbrinjavanju ovih
pacijenata prepoznata je kao veoma značajna. Cilj istraživanja bio je da se ispitaju percepcije
farmaceuta u primarnoj zdravstvenoj zaštiti o pružanju usluge pacijentima, kao i o
sprovedenoj edukaciji specijalizovanoj ka glavoboljama. Podaci su prikupljani putem ankete,
prilagođene prema prethodnom radu2 i obrađeni u programima SPSS i Microsoft Excel.
Popunjavanju ankete pristupilo je 43 farmaceuta iz primarne zdravstvene zaštite (90,7%
žene, raspon godina 27-64). Provera pouzdanosti ankete potvrđena je upotrebom Cronbach-
ovog testa (αB = 0,727; αC = 0,880). Najveći broj anketiranih farmaceuta smatra da pažljivo
sluša pacijente sa glavoboljom (65% uvek, 27,9% često), interakcije uvek proverava čak
44,7%, dok o pravilnoj primeni leka njih 86,04% uvek posavetuje pacijenta. Međutim,
34,88% prijavljuje da nikada ne kontaktira lekare ukoliko je lek skup, ne refundira se ili
izaziva neželjenu reakciju koja ograničava primenu, a 32,55% samo ponekad to učini. Većina
farmaceuta smatra da je edukacija korisna za bolje razumevanje pacijenata i savetovanje o
glavoboljama (97,67-100%), dok nešto manji procenat (93,02%) smatra da je edukacija
korisna da lakše prepoznaju pacijenta sa migrenom i upute ga lekaru. Percepcija većine
farmaceuta je da savetuje pacijente o terapiji glavobolje i bez prethodne edukacije, ali da bi
uz edukaciju usluga koju pružaju bila kompletnija. Rezultati studije upućuju da buduće
edukacije treba fokusirati na unapređenje komunikacije sa lekarima., Since headaches represent one of the most common disabling conditions in the world1
and can be treated with over-the-counter drugs, the role of pharmacists in caring for these
patients has been recognized as very important. The research aim was to review primary
health care pharmacists’ perception regarding patient service they provide and the
conducted education devoted to headaches. Data were collected through a survey adapted
from the published article 2 and analysed in SPSS and Microsoft Excel. The survey was
completed by 43 primary health care pharmacists (90.7% women, age 27-64). The survey
reliability was verified using the Cronbach’s test (αB = 0.727; αC = 0.880). Most of the
surveyed pharmacists believe that they listen carefully to patients with headaches (65%
always, 27.9% often), 44.7% always check interactions, while 86.04% always advise the
patient on proper drug administration. However, 34.88% report that they never contact
doctors if the drug is expensive, not reimbursable or causes an adverse reaction that limits
its use, and 32.55% only sometimes do so. Most pharmacists believe education was useful to
better understand patients and counsel them about headaches (97.67-100%), while a
slightly smaller percentage (93.02%) thinks it helped them learn to identify a migraine
patient and refer him to a doctor. The perception of most pharmacists is that they advise
patients on headache treatment even without prior education, but after it, the service would
be more complete. The study results indicate that future education should focus on
improving communication with doctors.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti, Pharmacists’ perception about providing services to patients with headaches in primary care",
volume = "72",
number = "4 suplement",
pages = "S264-S265",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4387"
}

Homšek, A., Jovanović, M., Roganović, M., Kovačević, M., Ćulafić, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S264-S265.
https://hdl.handle.net/21.15107/rcub_farfar_4387

Homšek A, Jovanović M, Roganović M, Kovačević M, Ćulafić M, Vezmar-Kovačević S, Vučićević K, Miljković B. Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4 suplement):S264-S265.
https://hdl.handle.net/21.15107/rcub_farfar_4387 .

Homšek, Ana, Jovanović, Marija, Roganović, Maša, Kovačević, Milena, Ćulafić, Milica, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Percepcija farmaceuta o pružanju usluge pacijentima sa glavoboljom u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S264-S265,
https://hdl.handle.net/21.15107/rcub_farfar_4387 .

TY  - CONF
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4396
AB  - Uverenja pacijenata mogu značajno uticati na stepen adherence i ishode terapije
hroničnih oboljenja. Cilj istraživanja bila je procena negativnih stavova (zabrinutosti)
odraslih pacijenata prema primeni terapije u lečenju astme i hronične opstruktivne bolesti
pluća (HOBP). Upitnik je obuhvatio demografske, podatke o terapiji, podatke o kontroli
bolesti (modified Medical Research Council–mMRC u HOBP, i Asthma Control Test–ACT u
astmi), i stavovima u pogledu zabrinutosti (Beliefs about Medicines Questionnaire-BMQ).
Korišćena je petostepena Likertova skala (1-uopšte se ne slažem, do 5–u potpunosti se
slažem). Analiza je izvršena primenom SPSS softvera (ver. 27). Istraživanjem je obuhvaćeno
145 pacijenata, 80 sa HOBP (55,2%) i 65 sa astmom (44,8%). Adekvatna kontrola bolesti
zabeležena je kod 42% (45% mMRC<2, 38,5% ACT≥20). Prosečna vrednost skora
zabrinutosti iznosila je 14,7±4,2 (opseg 6-25). Vrednost se nije statistički značajno
razlikovala između pacijenata sa astmom i HOBP, niti u zavisnosti od dužine trajanja bolesti.
Zabrinutost zbog primene lekova izrazilo je 55,9% pacijenata, dugoročnih posledica 44,1%,
razvoja zavisnosti 32,4%, nepoznavanja lekova 29,7% i uticaja na svakodnevni život 24,1%.
Literaturni podaci ukazuju na jaku povezanost negativnih stavova prema lekovima sa nižim
stepenom adherence, što nije bila tema našeg istraživanja, ali se može pretpostaviti da ti
rezultati doprinose lošoj kontroli bolesti u ispitivanoj grupi (<50%). Savetovanje pacijenata
u javnim apotekama o značaju redovne primene i odnosu korist/rizik od primene lekova u
lečenju astme i HOBP može biti značajna intervencija ka unapređenju stavova i ishoda
terapije.
AB  - Patients’ beliefs can significantly impact the adherence and outcomes of chronic
disease therapy. The aim of the study was to assess the negative attitudes (concerns) of adult
patients towards the use of medications for asthma and chronic obstructive pulmonary
disease (COPD). The questionnaire included demographics, data on therapy, disease control
(modified Medical Research Council-mMRC for COPD, and Asthma Control Test-ACT), and
concerns (Beliefs about Medicines Questionnaire-BMQ). A five-point Likert scale was used
(1-strongly disagree, to 5-strongly agree). Analysis was performed using SPSS software (ver.
27). The study included 145 patients, 80 COPD (55.2%) and 65 asthma (44.8%). Adequate
disease control was observed in 42% (45% mMRC <2, 38.5% ACT≥20). The mean concern
score was 14.7±4.2 (range 6–25). The score did not differ significantly between the patients
with asthma and COPD, nor depending on the disease duration. Concerns about the regular
use of medications were expressed by 55.9%, long-term consequences 44.1%, development
of addiction 32.4%, lack of knowledge 29.7% and the impact on everyday life 24.1%.
Literature data indicate a strong correlation between negative attitudes towards
medications with a lower level of adherence. It can be assumed that these results contribute
to poor disease control observed in our study (<50%). Patients’ counseling on the
importance of regular use and the benefit/risk ratio of asthma and COPD medications can be
a meaningful intervention in improving attitudes and therapy outcomes.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima
T1  - Concerns about medications in patients with chronic respiratory disease
VL  - 72
IS  - 4 Suplement
SP  - S256
EP  - S257
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4396
ER  - 

@conference{
author = "Kovačević, Milena and Ćulafić, Milica and Roganović, Maša and Jovanović, Marija and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2022",
abstract = "Uverenja pacijenata mogu značajno uticati na stepen adherence i ishode terapije
hroničnih oboljenja. Cilj istraživanja bila je procena negativnih stavova (zabrinutosti)
odraslih pacijenata prema primeni terapije u lečenju astme i hronične opstruktivne bolesti
pluća (HOBP). Upitnik je obuhvatio demografske, podatke o terapiji, podatke o kontroli
bolesti (modified Medical Research Council–mMRC u HOBP, i Asthma Control Test–ACT u
astmi), i stavovima u pogledu zabrinutosti (Beliefs about Medicines Questionnaire-BMQ).
Korišćena je petostepena Likertova skala (1-uopšte se ne slažem, do 5–u potpunosti se
slažem). Analiza je izvršena primenom SPSS softvera (ver. 27). Istraživanjem je obuhvaćeno
145 pacijenata, 80 sa HOBP (55,2%) i 65 sa astmom (44,8%). Adekvatna kontrola bolesti
zabeležena je kod 42% (45% mMRC<2, 38,5% ACT≥20). Prosečna vrednost skora
zabrinutosti iznosila je 14,7±4,2 (opseg 6-25). Vrednost se nije statistički značajno
razlikovala između pacijenata sa astmom i HOBP, niti u zavisnosti od dužine trajanja bolesti.
Zabrinutost zbog primene lekova izrazilo je 55,9% pacijenata, dugoročnih posledica 44,1%,
razvoja zavisnosti 32,4%, nepoznavanja lekova 29,7% i uticaja na svakodnevni život 24,1%.
Literaturni podaci ukazuju na jaku povezanost negativnih stavova prema lekovima sa nižim
stepenom adherence, što nije bila tema našeg istraživanja, ali se može pretpostaviti da ti
rezultati doprinose lošoj kontroli bolesti u ispitivanoj grupi (<50%). Savetovanje pacijenata
u javnim apotekama o značaju redovne primene i odnosu korist/rizik od primene lekova u
lečenju astme i HOBP može biti značajna intervencija ka unapređenju stavova i ishoda
terapije., Patients’ beliefs can significantly impact the adherence and outcomes of chronic
disease therapy. The aim of the study was to assess the negative attitudes (concerns) of adult
patients towards the use of medications for asthma and chronic obstructive pulmonary
disease (COPD). The questionnaire included demographics, data on therapy, disease control
(modified Medical Research Council-mMRC for COPD, and Asthma Control Test-ACT), and
concerns (Beliefs about Medicines Questionnaire-BMQ). A five-point Likert scale was used
(1-strongly disagree, to 5-strongly agree). Analysis was performed using SPSS software (ver.
27). The study included 145 patients, 80 COPD (55.2%) and 65 asthma (44.8%). Adequate
disease control was observed in 42% (45% mMRC <2, 38.5% ACT≥20). The mean concern
score was 14.7±4.2 (range 6–25). The score did not differ significantly between the patients
with asthma and COPD, nor depending on the disease duration. Concerns about the regular
use of medications were expressed by 55.9%, long-term consequences 44.1%, development
of addiction 32.4%, lack of knowledge 29.7% and the impact on everyday life 24.1%.
Literature data indicate a strong correlation between negative attitudes towards
medications with a lower level of adherence. It can be assumed that these results contribute
to poor disease control observed in our study (<50%). Patients’ counseling on the
importance of regular use and the benefit/risk ratio of asthma and COPD medications can be
a meaningful intervention in improving attitudes and therapy outcomes.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima, Concerns about medications in patients with chronic respiratory disease",
volume = "72",
number = "4 Suplement",
pages = "S256-S257",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4396"
}

Kovačević, M., Ćulafić, M., Roganović, M., Jovanović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2022). Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 Suplement), S256-S257.
https://hdl.handle.net/21.15107/rcub_farfar_4396

Kovačević M, Ćulafić M, Roganović M, Jovanović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima. in Arhiv za farmaciju. 2022;72(4 Suplement):S256-S257.
https://hdl.handle.net/21.15107/rcub_farfar_4396 .

Kovačević, Milena, Ćulafić, Milica, Roganović, Maša, Jovanović, Marija, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Zabrinutost u vezi sa primenom lekova kod pacijenata sa hroničnim respiratornim oboljenjima" in Arhiv za farmaciju, 72, no. 4 Suplement (2022):S256-S257,
https://hdl.handle.net/21.15107/rcub_farfar_4396 .

TY  - CONF
AU  - Kovačević, Milena
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Roganović, Maša
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4386
AB  - Primena benzodiazepina kod starijih pacijenata povezana je sa brojnim neželjenim
ishodima, poput povećanog rizika od pada, fraktura, troškova u zdravstvenom sistemu, pa
čak i smrtnih ishoda. Cilj rada bio je određivanje učestalosti primene benzodiazepina kod
pacijenata starosti ≥65 godina, i procena povezanosti njihove primene sa karakteristikama
pacijenata. Podaci su prikupljeni prospektivno u javnim apotekama primenom upitnika koji
su obuhvatili demografske, kliničke i karakteristike terapije pacijenta. Obrada rezultata
izvršena je primenom softvera SPSS (ver. 25). U istraživanju je učestvovalo 287 pacijenata,
prosečne starosti 72,2±5,8 godina (ukupan opseg 65-91). Prosečan broj lekova po pacijentu
iznosio je 7,6±2,2 (4-18), dok je prosečan broj indikacija iznosio 4,5±1,7 (1-11). Ukupna
zastupljenost benzodiazepina iznosila je 28,9%, od čega su dugodelujući bili primenjivani
kod 24.0%, a kratkodelujući kod 5,2% pacijenata. Najčešće primenjivan lek iz ove grupe bio
je bromazepam (17,1%), potom diazepam (7.0%), lorazepam (3,8%) i alprazolam (1,4%). U
grupi pacijenata starosti 65-69 godina prevalenca primene benzodiazepina iznosila je 29,3%,
70-74 godina 33,7%, 75-80 godina 23,3% i kod starijih od 80 godina 24.0%. Primena
benzodiazepina bila je statistički značajno češća kod pacijenata sa dijagnozom anksioznosti,
drugog mentalnog oboljenja, ali i primenom bisfosfonata, analgetika ili biljnog leka ekstrakta
lista Ginko biloba (p<0,05). Određena je visoka učestalost primene benzodiazepina kod
starijih pacijenata. Farmaceuti u javnim apotekama mogu imati značajnu ulogu u proceni i
minimizaciji rizika od neželjenog događaja, koji uključuju savetovanje pacijenata o prevenciji
padova, ali i mogućnostima postepene obustave ovih lekova kada ne postoji ubedljiva
indikacija za njihovu dugotrajnu primenu.
AB  - The use of benzodiazepines in elderly patients is associated with the numerous adverse
outcomes, such as an increased risk of falls, fractures, health care costs, and even mortality.
The aim was to investigate the frequency of benzodiazepine use in patients aged ≥65 years,
and to explore the association of their use with patient characteristics. Demographic, clinical,
and therapy characteristics were collected prospectively in the community pharmacies. Data
analysis was performed using SPSS software (ver. 25). The study included 287 patients, with
a mean age of 72.2±5.8 years (total range 65-91), the average number of drugs 7.6±2.2 (4-
18), and the average number of indications 4.5±1.7 (1-11). The total prevalence of
benzodiazepine use was 28.9%, long-acting 24.0% and short-acting 5.2%. The most
commonly used was bromazepam (17.1%), followed by diazepam (7.0%), lorazepam (3.8%)
and alprazolam (1.4%). In the patients aged 65-69 years, the prevalence of benzodiazepine
use was 29.3%, 70-74 years 33.7%, 75-80 years 23.3% and in ≥80 years 24.0%. The use of
benzodiazepines was statistically significantly more common in patients diagnosed with
anxiety, other mental illness, but also with the comedication with bisphosphonates,
analgesics or herbal medicine Ginkgo biloba leaf extract (p<0.05). A high frequency of
benzodiazepine use was determined in elderly patients. Community pharmacists can play a
significant role in assessing and minimizing the risk of adverse events. Interventions may
include counseling on the prevention of falls, but also the possibility of drug discontinuation
when there is no convincing indication for their long-term use.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti
T1  - Frequency of benzodiazepine use in elderly primary care patients
VL  - 72
IS  - 4 suplement
SP  - S258
EP  - S259
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4386
ER  - 

@conference{
author = "Kovačević, Milena and Jovanović, Marija and Ćulafić, Milica and Roganović, Maša and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2022",
abstract = "Primena benzodiazepina kod starijih pacijenata povezana je sa brojnim neželjenim
ishodima, poput povećanog rizika od pada, fraktura, troškova u zdravstvenom sistemu, pa
čak i smrtnih ishoda. Cilj rada bio je određivanje učestalosti primene benzodiazepina kod
pacijenata starosti ≥65 godina, i procena povezanosti njihove primene sa karakteristikama
pacijenata. Podaci su prikupljeni prospektivno u javnim apotekama primenom upitnika koji
su obuhvatili demografske, kliničke i karakteristike terapije pacijenta. Obrada rezultata
izvršena je primenom softvera SPSS (ver. 25). U istraživanju je učestvovalo 287 pacijenata,
prosečne starosti 72,2±5,8 godina (ukupan opseg 65-91). Prosečan broj lekova po pacijentu
iznosio je 7,6±2,2 (4-18), dok je prosečan broj indikacija iznosio 4,5±1,7 (1-11). Ukupna
zastupljenost benzodiazepina iznosila je 28,9%, od čega su dugodelujući bili primenjivani
kod 24.0%, a kratkodelujući kod 5,2% pacijenata. Najčešće primenjivan lek iz ove grupe bio
je bromazepam (17,1%), potom diazepam (7.0%), lorazepam (3,8%) i alprazolam (1,4%). U
grupi pacijenata starosti 65-69 godina prevalenca primene benzodiazepina iznosila je 29,3%,
70-74 godina 33,7%, 75-80 godina 23,3% i kod starijih od 80 godina 24.0%. Primena
benzodiazepina bila je statistički značajno češća kod pacijenata sa dijagnozom anksioznosti,
drugog mentalnog oboljenja, ali i primenom bisfosfonata, analgetika ili biljnog leka ekstrakta
lista Ginko biloba (p<0,05). Određena je visoka učestalost primene benzodiazepina kod
starijih pacijenata. Farmaceuti u javnim apotekama mogu imati značajnu ulogu u proceni i
minimizaciji rizika od neželjenog događaja, koji uključuju savetovanje pacijenata o prevenciji
padova, ali i mogućnostima postepene obustave ovih lekova kada ne postoji ubedljiva
indikacija za njihovu dugotrajnu primenu., The use of benzodiazepines in elderly patients is associated with the numerous adverse
outcomes, such as an increased risk of falls, fractures, health care costs, and even mortality.
The aim was to investigate the frequency of benzodiazepine use in patients aged ≥65 years,
and to explore the association of their use with patient characteristics. Demographic, clinical,
and therapy characteristics were collected prospectively in the community pharmacies. Data
analysis was performed using SPSS software (ver. 25). The study included 287 patients, with
a mean age of 72.2±5.8 years (total range 65-91), the average number of drugs 7.6±2.2 (4-
18), and the average number of indications 4.5±1.7 (1-11). The total prevalence of
benzodiazepine use was 28.9%, long-acting 24.0% and short-acting 5.2%. The most
commonly used was bromazepam (17.1%), followed by diazepam (7.0%), lorazepam (3.8%)
and alprazolam (1.4%). In the patients aged 65-69 years, the prevalence of benzodiazepine
use was 29.3%, 70-74 years 33.7%, 75-80 years 23.3% and in ≥80 years 24.0%. The use of
benzodiazepines was statistically significantly more common in patients diagnosed with
anxiety, other mental illness, but also with the comedication with bisphosphonates,
analgesics or herbal medicine Ginkgo biloba leaf extract (p<0.05). A high frequency of
benzodiazepine use was determined in elderly patients. Community pharmacists can play a
significant role in assessing and minimizing the risk of adverse events. Interventions may
include counseling on the prevention of falls, but also the possibility of drug discontinuation
when there is no convincing indication for their long-term use.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti, Frequency of benzodiazepine use in elderly primary care patients",
volume = "72",
number = "4 suplement",
pages = "S258-S259",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4386"
}

Kovačević, M., Jovanović, M., Ćulafić, M., Roganović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2022). Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S258-S259.
https://hdl.handle.net/21.15107/rcub_farfar_4386

Kovačević M, Jovanović M, Ćulafić M, Roganović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti. in Arhiv za farmaciju. 2022;72(4 suplement):S258-S259.
https://hdl.handle.net/21.15107/rcub_farfar_4386 .

Kovačević, Milena, Jovanović, Marija, Ćulafić, Milica, Roganović, Maša, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Učestalost primene benzodiazepina kod starijih pacijenata u primarnoj zdravstvenoj zaštiti" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S258-S259,
https://hdl.handle.net/21.15107/rcub_farfar_4386 .

TY  - JOUR
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Jovanović, Marija
AU  - Roganović, Maša
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4383
AB  - COPD is a chronic condition requiring care from a multidisciplinary team in which pharma-
cists play an important role. We aimed to evaluate the impact of structured pharmacist-patient counsel-
ing on patients’ knowledge, and attitudes about medicines and the impact of COPD on patients’ health
status. A prospective study was conducted in ten community pharmacies. Patients were counseled using
a detailed approach after completing validated questionnaires. The patients returned to a pharmacy for
a follow-up after three months. Four validated questionnaires have been used to assess different aspects
of patient’s knowledge about the disease, their attitudes about medicines, and the impact of the disease on
patients’ health status: COPD Assessment Test (CAT), Modified Medical Research Council Dyspnea Scale
(mMRC), Bristol COPD Knowledge Questionnaire (BCKQ), and The Beliefs about Medicines Question-
naire (BMQ). Pharmacists recruited 83 COPD patients, from which 73 patients attended a follow-up visit.
Before pharmacist intervention, the CAT median score was 20. After counseling, the CAT score decreased
to 18 (p < 0.05). The highest improvement in patient knowledge was observed for inhaled bronchodila-
tors (28.2%), vaccination (25.8%), oral steroids (24.4%), and smoking (24.2%). The median score for
necessity increased, whereas the harm and concern median scores considerably decreased (p < 0.05) after
counseling. The results showed significant improvements in all aspects covered throughout pharmacist-
patient counseling. Based on our results, the proactive role of the pharmacist in the care of COPD patients
may be beneficial to patients, physicians, and healthcare by improving care, and alleviating the strain on
overloaded doctors by containing the costs.
PB  - Polish Pharmaceutical Society
T2  - Acta Poloniae Pharmaceutica - Drug Research
T1  - Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status
VL  - 79
IS  - 5
SP  - 725
EP  - 734
DO  - 10.32383/appdr/155353
ER  - 

@article{
author = "Ćulafić, Milica and Kovačević, Milena and Jovanović, Marija and Roganović, Maša and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "COPD is a chronic condition requiring care from a multidisciplinary team in which pharma-
cists play an important role. We aimed to evaluate the impact of structured pharmacist-patient counsel-
ing on patients’ knowledge, and attitudes about medicines and the impact of COPD on patients’ health
status. A prospective study was conducted in ten community pharmacies. Patients were counseled using
a detailed approach after completing validated questionnaires. The patients returned to a pharmacy for
a follow-up after three months. Four validated questionnaires have been used to assess different aspects
of patient’s knowledge about the disease, their attitudes about medicines, and the impact of the disease on
patients’ health status: COPD Assessment Test (CAT), Modified Medical Research Council Dyspnea Scale
(mMRC), Bristol COPD Knowledge Questionnaire (BCKQ), and The Beliefs about Medicines Question-
naire (BMQ). Pharmacists recruited 83 COPD patients, from which 73 patients attended a follow-up visit.
Before pharmacist intervention, the CAT median score was 20. After counseling, the CAT score decreased
to 18 (p < 0.05). The highest improvement in patient knowledge was observed for inhaled bronchodila-
tors (28.2%), vaccination (25.8%), oral steroids (24.4%), and smoking (24.2%). The median score for
necessity increased, whereas the harm and concern median scores considerably decreased (p < 0.05) after
counseling. The results showed significant improvements in all aspects covered throughout pharmacist-
patient counseling. Based on our results, the proactive role of the pharmacist in the care of COPD patients
may be beneficial to patients, physicians, and healthcare by improving care, and alleviating the strain on
overloaded doctors by containing the costs.",
publisher = "Polish Pharmaceutical Society",
journal = "Acta Poloniae Pharmaceutica - Drug Research",
title = "Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status",
volume = "79",
number = "5",
pages = "725-734",
doi = "10.32383/appdr/155353"
}

Ćulafić, M., Kovačević, M., Jovanović, M., Roganović, M., Vezmar-Kovačević, S., Vučićević, K.,& Miljković, B.. (2022). Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status. in Acta Poloniae Pharmaceutica - Drug Research
Polish Pharmaceutical Society., 79(5), 725-734.
https://doi.org/10.32383/appdr/155353

Ćulafić M, Kovačević M, Jovanović M, Roganović M, Vezmar-Kovačević S, Vučićević K, Miljković B. Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status. in Acta Poloniae Pharmaceutica - Drug Research. 2022;79(5):725-734.
doi:10.32383/appdr/155353 .

Ćulafić, Milica, Kovačević, Milena, Jovanović, Marija, Roganović, Maša, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Miljković, Branislava, "Community pharmacist-driven interventions in COPD: improving knowledge, attitude and health status" in Acta Poloniae Pharmaceutica - Drug Research, 79, no. 5 (2022):725-734,
https://doi.org/10.32383/appdr/155353 . .

TY  - CONF
AU  - Ćulafić, Milica
AU  - Đorđević, J.
AU  - Stanković, Sanja
AU  - Štulić, Miloš
AU  - Pejić, Nina
AU  - Vezmar-Kovačević, Sandra
AU  - Oluić, Branislav
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4337
PB  - Elsevier B.V.
C3  - Clinica Chimica Acta
T1  - Adverse drug reactions of tacrolimus after liver transplant - Our Experience
VL  - 530
IS  - Supplement 1
SP  - S448
EP  - S448
DO  - doi.org/10.1016/j.cca.2022.04.395
ER  - 

@conference{
author = "Ćulafić, Milica and Đorđević, J. and Stanković, Sanja and Štulić, Miloš and Pejić, Nina and Vezmar-Kovačević, Sandra and Oluić, Branislav and Miljković, Branislava and Ćulafić, Đorđe",
year = "2022",
publisher = "Elsevier B.V.",
journal = "Clinica Chimica Acta",
title = "Adverse drug reactions of tacrolimus after liver transplant - Our Experience",
volume = "530",
number = "Supplement 1",
pages = "S448-S448",
doi = "doi.org/10.1016/j.cca.2022.04.395"
}

Ćulafić, M., Đorđević, J., Stanković, S., Štulić, M., Pejić, N., Vezmar-Kovačević, S., Oluić, B., Miljković, B.,& Ćulafić, Đ.. (2022). Adverse drug reactions of tacrolimus after liver transplant - Our Experience. in Clinica Chimica Acta
Elsevier B.V.., 530(Supplement 1), S448-S448.
https://doi.org/doi.org/10.1016/j.cca.2022.04.395

Ćulafić M, Đorđević J, Stanković S, Štulić M, Pejić N, Vezmar-Kovačević S, Oluić B, Miljković B, Ćulafić Đ. Adverse drug reactions of tacrolimus after liver transplant - Our Experience. in Clinica Chimica Acta. 2022;530(Supplement 1):S448-S448.
doi:doi.org/10.1016/j.cca.2022.04.395 .

Ćulafić, Milica, Đorđević, J., Stanković, Sanja, Štulić, Miloš, Pejić, Nina, Vezmar-Kovačević, Sandra, Oluić, Branislav, Miljković, Branislava, Ćulafić, Đorđe, "Adverse drug reactions of tacrolimus after liver transplant - Our Experience" in Clinica Chimica Acta, 530, no. Supplement 1 (2022):S448-S448,
https://doi.org/doi.org/10.1016/j.cca.2022.04.395 . .

TY  - CONF
AU  - Ćulafić, Milica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4443
AB  - Pharmacotherapy after liver transplantation include a combination of
immunosuppressants to prevent graft rejection (calcineurin inhibitor, antimetabolite and
corticosteroid) and antibacterial, antifungal and antiviral prophylaxis. In addition to
potential preexisting comorbidities, metabolic complications/chronic conditions occur as a
result of long-term immunosuppression. Given the complexity of post-transplant therapy
and the pharmacokinetics of drugs, interactions are expected. The study aimed to detect the
safety profile of immunosuppressants, including the assessment of drug-drug interactions.
The study involved patients monitored at the Clinic of Gastroenterology and Hepatology,
Clinical Center of Serbia, after liver transplantation, from November 2015 to November
2019. Medical records and laboratory reports were reviewed in the period of three months
after transplantation. Adverse drug reactions (ADRs) have been reported. Interactions were
analyzed using two databases: Lexicomp and Epocrates. We included 54 patients aged 44.7 ±
12.3, and recorded 252 follow-ups/hospitalizations. The average number of drugs per
patient was 7. We noted following ADRs: Tacrolimus - hypomagnesemia (90.3%), infections
(22.2%), nephrotoxicity (18.7%); mycophenolate mofetil - leukopenia 20.2%, increase in
lactate dehydrogenase 11.1%, diarrhea 5.4%; everolimus - hypercholesterolaemia 25.0%,
hypertriglyceridemia 12.3%. Potential drug-drug interactions in Lexicomp (225 D; 12 X) and
Epocrates (543 monitor/modify; 139 avoid) were identified. Recognition, management and
prevention of ADRs including timely resolution of drug-drug interactions is essential in
improving long-term outcomes after liver transplantation. Frequent therapeutic drug
monitoring, identification of clinical signs and parameters, and therapy optimization for each
individual patient is a necessity. Hence, clinical transplant pharmacists have a vital role in
multidisciplinary transplant team (1).
AB  - Farmakoterapija nakon transplantacije jetre podrazumeva kombinovanu primenu
imunosupresivnih lekova koji preveniraju odbacivanje grafta (inhibitor kalcineurina,
antimetabolit i kortikosteroid) i profilaksu antibioticima, antiviroticima i antimikoticima.
Osim potencijalno prisutnih komorbiditeta pre transplantacije, javljaju se i metaboličke
komplikacije/hronična stanja kao posledica dugotrajne imunosupresije. Imajući na umu
kompleksnost postransplantacione terapije i farmakokinetički profil lekova, interakcije su
očekivane. Studija je imala za cilj detektovanje bezbednosnog profila imunosupresiva,
uključujući i procenu lek-lek interakcija. U studiji su učestvovali pacijenti koji se prate na
Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije, nakon transplantacije
jetre, od novembra 2015. do novembra 2019. Pregledani su medicinska dokumentacija i
laboratorijski izveštaji u periodu od tri meseca posle transplantacije. Zabeležene su
neželjene reakcije na lekove (NRL). Interakcije su analizirane primenom dve baze podataka:
Lexicomp i Epocrates. Uključena su 54 pacijenta starosti 44,7±12,3, zabeležena 252
kontrolna pregleda/hospitalizacije. Prosečan broj lekova po pacijentu bio je 7. Opisane su
NRL kao posledica primene takrolimusa: hipomagnezemija (90,3%), infekcije (22,2%),
nefrotoksičnost (18,7%); mikofenolat mofetila: leukopenija 20,2%, porast laktat
dehidrogenaze 11,1%, dijareja 5,4%; everolimusa: hiperholesterolemija 25,0%,
hipertrigliceridemija 12,3%. Identifikovan je broj potencijalnih interakcija u Lexicompu (225
D; 12 X) i Epocratesu (543 pratiti/modifikovati; 139 izbegavati). Prepoznavanje, upravljanje
i prevencija NRL uključujući i pravovremeno rešavanje lek-lek interakcija predstavlja
značajan aspekt nakon transplantacije jetre u poboljšanju dugoročnog ishoda. Neophodno je
često terapijsko praćenje lekova, identifikacija kliničkih znakova i parametara, te
optimizacija terapije za svakog individualnog pacijenta. Transplantacioni klinički farmaceuti
stoga imaju važnu ulogu u multidisciplinarnom transplantacionom timu (1).
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Safety profile of immunosuppressants: Our experience
T1  - Bezbednosni profil imunosupresiva: naša iskustva
VL  - 72
IS  - 4 suplement
SP  - S48
EP  - S49
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4443
ER  - 

@conference{
author = "Ćulafić, Milica",
year = "2022",
abstract = "Pharmacotherapy after liver transplantation include a combination of
immunosuppressants to prevent graft rejection (calcineurin inhibitor, antimetabolite and
corticosteroid) and antibacterial, antifungal and antiviral prophylaxis. In addition to
potential preexisting comorbidities, metabolic complications/chronic conditions occur as a
result of long-term immunosuppression. Given the complexity of post-transplant therapy
and the pharmacokinetics of drugs, interactions are expected. The study aimed to detect the
safety profile of immunosuppressants, including the assessment of drug-drug interactions.
The study involved patients monitored at the Clinic of Gastroenterology and Hepatology,
Clinical Center of Serbia, after liver transplantation, from November 2015 to November
2019. Medical records and laboratory reports were reviewed in the period of three months
after transplantation. Adverse drug reactions (ADRs) have been reported. Interactions were
analyzed using two databases: Lexicomp and Epocrates. We included 54 patients aged 44.7 ±
12.3, and recorded 252 follow-ups/hospitalizations. The average number of drugs per
patient was 7. We noted following ADRs: Tacrolimus - hypomagnesemia (90.3%), infections
(22.2%), nephrotoxicity (18.7%); mycophenolate mofetil - leukopenia 20.2%, increase in
lactate dehydrogenase 11.1%, diarrhea 5.4%; everolimus - hypercholesterolaemia 25.0%,
hypertriglyceridemia 12.3%. Potential drug-drug interactions in Lexicomp (225 D; 12 X) and
Epocrates (543 monitor/modify; 139 avoid) were identified. Recognition, management and
prevention of ADRs including timely resolution of drug-drug interactions is essential in
improving long-term outcomes after liver transplantation. Frequent therapeutic drug
monitoring, identification of clinical signs and parameters, and therapy optimization for each
individual patient is a necessity. Hence, clinical transplant pharmacists have a vital role in
multidisciplinary transplant team (1)., Farmakoterapija nakon transplantacije jetre podrazumeva kombinovanu primenu
imunosupresivnih lekova koji preveniraju odbacivanje grafta (inhibitor kalcineurina,
antimetabolit i kortikosteroid) i profilaksu antibioticima, antiviroticima i antimikoticima.
Osim potencijalno prisutnih komorbiditeta pre transplantacije, javljaju se i metaboličke
komplikacije/hronična stanja kao posledica dugotrajne imunosupresije. Imajući na umu
kompleksnost postransplantacione terapije i farmakokinetički profil lekova, interakcije su
očekivane. Studija je imala za cilj detektovanje bezbednosnog profila imunosupresiva,
uključujući i procenu lek-lek interakcija. U studiji su učestvovali pacijenti koji se prate na
Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije, nakon transplantacije
jetre, od novembra 2015. do novembra 2019. Pregledani su medicinska dokumentacija i
laboratorijski izveštaji u periodu od tri meseca posle transplantacije. Zabeležene su
neželjene reakcije na lekove (NRL). Interakcije su analizirane primenom dve baze podataka:
Lexicomp i Epocrates. Uključena su 54 pacijenta starosti 44,7±12,3, zabeležena 252
kontrolna pregleda/hospitalizacije. Prosečan broj lekova po pacijentu bio je 7. Opisane su
NRL kao posledica primene takrolimusa: hipomagnezemija (90,3%), infekcije (22,2%),
nefrotoksičnost (18,7%); mikofenolat mofetila: leukopenija 20,2%, porast laktat
dehidrogenaze 11,1%, dijareja 5,4%; everolimusa: hiperholesterolemija 25,0%,
hipertrigliceridemija 12,3%. Identifikovan je broj potencijalnih interakcija u Lexicompu (225
D; 12 X) i Epocratesu (543 pratiti/modifikovati; 139 izbegavati). Prepoznavanje, upravljanje
i prevencija NRL uključujući i pravovremeno rešavanje lek-lek interakcija predstavlja
značajan aspekt nakon transplantacije jetre u poboljšanju dugoročnog ishoda. Neophodno je
često terapijsko praćenje lekova, identifikacija kliničkih znakova i parametara, te
optimizacija terapije za svakog individualnog pacijenta. Transplantacioni klinički farmaceuti
stoga imaju važnu ulogu u multidisciplinarnom transplantacionom timu (1).",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Safety profile of immunosuppressants: Our experience, Bezbednosni profil imunosupresiva: naša iskustva",
volume = "72",
number = "4 suplement",
pages = "S48-S49",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4443"
}

Ćulafić, M.. (2022). Safety profile of immunosuppressants: Our experience. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S48-S49.
https://hdl.handle.net/21.15107/rcub_farfar_4443

Ćulafić M. Safety profile of immunosuppressants: Our experience. in Arhiv za farmaciju. 2022;72(4 suplement):S48-S49.
https://hdl.handle.net/21.15107/rcub_farfar_4443 .

Ćulafić, Milica, "Safety profile of immunosuppressants: Our experience" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S48-S49,
https://hdl.handle.net/21.15107/rcub_farfar_4443 .

TY  - JOUR
AU  - Pejić, Nina
AU  - Stojković Lalošević, Milica
AU  - Štulić, Miloš
AU  - Ćulafić, Milica
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4343
AB  - Introduction: COVID-19 is an infectious disease, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and there have been outbreaks worldwide. The presentation may include unspecific and mild symptoms, myalgia, headaches, high fever, dry cough, severe dyspnea and acute respiratory distress syndrome (ARDS). Case study: We present a rare case of microscopic polyangiitis (MPA) with interstitial lung disease and without renal involvement misdiagnosed as COVID-19. Conclusions: Differential diagnosis of COVID-19 is extremely important, and must be correctly identified in order to proceed with correct treatment.
PB  - Journal of Infection in Developing Countries
T2  - Journal of Infection in Developing Countries
T1  - Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?
VL  - 16
IS  - 9
SP  - 1530
EP  - 1532
DO  - 10.3855/jidc.16401
ER  - 

@article{
author = "Pejić, Nina and Stojković Lalošević, Milica and Štulić, Miloš and Ćulafić, Milica and Ćulafić, Đorđe",
year = "2022",
abstract = "Introduction: COVID-19 is an infectious disease, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and there have been outbreaks worldwide. The presentation may include unspecific and mild symptoms, myalgia, headaches, high fever, dry cough, severe dyspnea and acute respiratory distress syndrome (ARDS). Case study: We present a rare case of microscopic polyangiitis (MPA) with interstitial lung disease and without renal involvement misdiagnosed as COVID-19. Conclusions: Differential diagnosis of COVID-19 is extremely important, and must be correctly identified in order to proceed with correct treatment.",
publisher = "Journal of Infection in Developing Countries",
journal = "Journal of Infection in Developing Countries",
title = "Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?",
volume = "16",
number = "9",
pages = "1530-1532",
doi = "10.3855/jidc.16401"
}

Pejić, N., Stojković Lalošević, M., Štulić, M., Ćulafić, M.,& Ćulafić, Đ.. (2022). Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?. in Journal of Infection in Developing Countries
Journal of Infection in Developing Countries., 16(9), 1530-1532.
https://doi.org/10.3855/jidc.16401

Pejić N, Stojković Lalošević M, Štulić M, Ćulafić M, Ćulafić Đ. Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?. in Journal of Infection in Developing Countries. 2022;16(9):1530-1532.
doi:10.3855/jidc.16401 .

Pejić, Nina, Stojković Lalošević, Milica, Štulić, Miloš, Ćulafić, Milica, Ćulafić, Đorđe, "Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?" in Journal of Infection in Developing Countries, 16, no. 9 (2022):1530-1532,
https://doi.org/10.3855/jidc.16401 . .

TY  - JOUR
AU  - Roganović, Maša
AU  - Homšek, Ana
AU  - Jovanović, Marija
AU  - Topić-Vučenović, Valentina
AU  - Ćulafić, Milica
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3960
AB  - Due to frequent clinical trial failures and consequently fewer new drug approvals, the need
for improvement in drug development has, to a certain extent, been met using model-based drug
development. Pharmacometrics is a part of pharmacology that quantifies drug behaviour,
treatment response and disease progression based on different models (pharmacokinetic - PK,
pharmacodynamic - PD, PK/PD models, etc.) and simulations. Regulatory bodies (European
Medicines Agency, Food and Drug Administration) encourage the use of modelling and
simulations to facilitate decision-making throughout all drug development phases. Moreover, the
identification of factors that contribute to variability provides a basis for dose individualisation in
routine clinical practice. This review summarises current knowledge regarding the application of
pharmacometrics in drug development and clinical practice with emphasis on the population
modelling approach.
AB  - Usled čestih neuspeha u kliničkim ispitivanjima i posledično manjeg broja odobrenja novih lekova, potreba za poboljšanjem u razvoju lekova je u određenoj meri zadovoljena korišćenjem pristupa razvoja lekova zasnovanog na modelu. Farmakometrija predstavlja granu farmakologije koja kvantifikuje ponašanje leka, odgovor na terapiju i napredovanje bolesti na osnovu različitih modela (farmakokinetički - FK, farmakodinamički - FD, FK/FD modeli itd.) i simulacija. Regulatorna tela (Evropska agencija za lekove, Uprava za hranu i lekove) podstiču primenu modelovanja i simulacija u svrhu lakšeg donošenja odluka tokom svih faza razvoja lekova. Štaviše, identifikacija faktora koji doprinose varijabilnosti predstavlja osnovu za individualizaciju doze u rutinskoj kliničkoj praksi. Ovaj revijalni rad sumira trenutno znanje u vezi sa primenom farmakometrije u razvoju lekova i kliničkoj praksi sa fokusom na populacionu analizu.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice
T1  - Koncept i upotreba populacionih farmakokinetičkih i farmakokinetičko/farmakodinamičkih modela u razvoju leka i kliničkoj praksi
VL  - 71
IS  - 4
SP  - 336
EP  - 353
DO  - 10.5937/arhfarm71-32901
ER  - 

@article{
author = "Roganović, Maša and Homšek, Ana and Jovanović, Marija and Topić-Vučenović, Valentina and Ćulafić, Milica and Miljković, Branislava and Vučićević, Katarina",
year = "2021",
abstract = "Due to frequent clinical trial failures and consequently fewer new drug approvals, the need
for improvement in drug development has, to a certain extent, been met using model-based drug
development. Pharmacometrics is a part of pharmacology that quantifies drug behaviour,
treatment response and disease progression based on different models (pharmacokinetic - PK,
pharmacodynamic - PD, PK/PD models, etc.) and simulations. Regulatory bodies (European
Medicines Agency, Food and Drug Administration) encourage the use of modelling and
simulations to facilitate decision-making throughout all drug development phases. Moreover, the
identification of factors that contribute to variability provides a basis for dose individualisation in
routine clinical practice. This review summarises current knowledge regarding the application of
pharmacometrics in drug development and clinical practice with emphasis on the population
modelling approach., Usled čestih neuspeha u kliničkim ispitivanjima i posledično manjeg broja odobrenja novih lekova, potreba za poboljšanjem u razvoju lekova je u određenoj meri zadovoljena korišćenjem pristupa razvoja lekova zasnovanog na modelu. Farmakometrija predstavlja granu farmakologije koja kvantifikuje ponašanje leka, odgovor na terapiju i napredovanje bolesti na osnovu različitih modela (farmakokinetički - FK, farmakodinamički - FD, FK/FD modeli itd.) i simulacija. Regulatorna tela (Evropska agencija za lekove, Uprava za hranu i lekove) podstiču primenu modelovanja i simulacija u svrhu lakšeg donošenja odluka tokom svih faza razvoja lekova. Štaviše, identifikacija faktora koji doprinose varijabilnosti predstavlja osnovu za individualizaciju doze u rutinskoj kliničkoj praksi. Ovaj revijalni rad sumira trenutno znanje u vezi sa primenom farmakometrije u razvoju lekova i kliničkoj praksi sa fokusom na populacionu analizu.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice, Koncept i upotreba populacionih farmakokinetičkih i farmakokinetičko/farmakodinamičkih modela u razvoju leka i kliničkoj praksi",
volume = "71",
number = "4",
pages = "336-353",
doi = "10.5937/arhfarm71-32901"
}

Roganović, M., Homšek, A., Jovanović, M., Topić-Vučenović, V., Ćulafić, M., Miljković, B.,& Vučićević, K.. (2021). Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 71(4), 336-353.
https://doi.org/10.5937/arhfarm71-32901

Roganović M, Homšek A, Jovanović M, Topić-Vučenović V, Ćulafić M, Miljković B, Vučićević K. Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice. in Arhiv za farmaciju. 2021;71(4):336-353.
doi:10.5937/arhfarm71-32901 .

Roganović, Maša, Homšek, Ana, Jovanović, Marija, Topić-Vučenović, Valentina, Ćulafić, Milica, Miljković, Branislava, Vučićević, Katarina, "Concept and utility of population pharmacokinetic and pharmacokinetic/ pharmacodynamic models in drug development and clinical practice" in Arhiv za farmaciju, 71, no. 4 (2021):336-353,
https://doi.org/10.5937/arhfarm71-32901 . .

TY  - THES
AU  - Ćulafić, Milica
PY  - 2020
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=7657
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:22814/bdef:Content/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=23047945
UR  - https://nardus.mpn.gov.rs/handle/123456789/17522
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3721
AB  - Циљ докторске дисертације био је да се идентифукују параметри који семогу користити у диференцијацији између симплекс стеатоза и NASH-a, те дасе истражи ефекат и процени безбедност комбиноване терапије метформиноми пентоксифилином у NASH-у. Проучаван је степен адхеренце у испитиванојпопулацији. Укупан број пацијената укључених у студију био је 148.Креиран је модел који је укључио 4 варијабле идентификоване каостатистички значајне (HOMA-IR, мокраћну киселину, феритин и ALT) названHUFA индекс. Забележена је површина испод оперативне криве 0,94 запредложени модел, сензитивност 70,3%, специфичност 95,1%, позитивнапредиктивна вредност 83,1% и негативна предиктивна вредност 90,0%, задетекцију NASH-а. Спроведена је терапија метформином и пентоксифилином уNASH кохорти у трајању од 6 месеци, док је група симплекс стеатоза служилакао контролна. Забележено је смањење вредности медијане мокраћне киселинеу серуму за 51μmol/L, калцијума за 0,27 mmol/L, повећање магнезијума за 0,11mmol/L. Побољшана је инсулинска резистенција кроз смањење HOMA-IR за 1,3.Уочено је значајно смањење медијане ALT за 24,0 IU/L, AST за 9,1 IU/L и GGT за10,8 IU/L. Нежељене реакције током примене терапије су описане као благе ипролазне. Процена адхеренце извршена је Morisky скалом: у групи симплексстеатоза било је 58% адхерентних у погледу њихове хроничне терапије, док је уNASH-у висок степен адхеренце уочен код 85% пацијената. Применом SMAQскале добијени су нижи проценти адхерентних у обе групе (42,3% vs 76,2%).HUFA индекс се показао значајним за рану детекцију некроинфламације уNAFLD-у. Комбинована терапија у NASH-у је довела до побољшањабиохемијских параметара. Детектован проценат неадхерентних пацијенатаомогућава правовремену интервенцију у сврху постизања бољих исхода лечења...
AB  - The aim of doctoral dissertation was to identify parameters important to differentiate simple steatosis from NASH and to explore efficacy and safety of metformin/pentoxifylline combined treatment in NASH. Level of adherence was also evaluated. Total number of patients included in the study was 148. A proposed model named HUFA index included 4 variables (HOMA-IR, serum Uric acid, Ferritin and ALT) that were shown to be statisticaly significant. An area under receiving operating curve of 0.94 was noted for the NASH detection model, with sensitivity of 70.3%, specificity of 95.1%, positive predicitive value of 83.1% and negative predicitive value of 90.0%. Metformin and pentoxifylline were introduced in NASH cohort for 6 month, while simple steatosis cohort served as control. Decrease in median value of uric acid and calcium was observed (51μmol/L and 0.27 mmol/L, respectively). Magnesium increased for 0.11 mmol/L. Insulin resistance improved as HOMA-IR reduced for 1.3. Decrease in median value of hepatic enzymes (ALT, AST, GGT) was detected: 24.0 IU/L, 9.1 IU/L and 10.8 IU/L, respectively. Adverse drug reaction that emerged were described as mild and transient. Adherence was evaluated using Morisky scale. In simple steatosis group only 58% of patients were adherent to their chronic treatment, while NASH cohort showed optimal adherence in 85% of cases. When SMAQ scale was used, lower percentage of adherence was detected in both cohorts (42,3% vs  76,2%). HUFA index is important for early detection of necroinflammation in NAFLD. Studied therapy showed improvement of biochemical parameters. Identification of nonadherent patients is important for timely intervention and consequently better treatment outcomes.
PB  - Универзитет у Београду, Фармацеутски факултет
T2  - Универзитет у Београду
T1  - Значај биохемијских параметара у диференцијацији нелкохолног стеатохепатитиса и процена исхода терапије и адхеренце, при примени метформина и пентоксифилина
EP  - 
UR  - https://hdl.handle.net/21.15107/rcub_nardus_17522
ER  - 

@phdthesis{
author = "Ćulafić, Milica",
year = "2020",
abstract = "Циљ докторске дисертације био је да се идентифукују параметри који семогу користити у диференцијацији између симплекс стеатоза и NASH-a, те дасе истражи ефекат и процени безбедност комбиноване терапије метформиноми пентоксифилином у NASH-у. Проучаван је степен адхеренце у испитиванојпопулацији. Укупан број пацијената укључених у студију био је 148.Креиран је модел који је укључио 4 варијабле идентификоване каостатистички значајне (HOMA-IR, мокраћну киселину, феритин и ALT) названHUFA индекс. Забележена је површина испод оперативне криве 0,94 запредложени модел, сензитивност 70,3%, специфичност 95,1%, позитивнапредиктивна вредност 83,1% и негативна предиктивна вредност 90,0%, задетекцију NASH-а. Спроведена је терапија метформином и пентоксифилином уNASH кохорти у трајању од 6 месеци, док је група симплекс стеатоза служилакао контролна. Забележено је смањење вредности медијане мокраћне киселинеу серуму за 51μmol/L, калцијума за 0,27 mmol/L, повећање магнезијума за 0,11mmol/L. Побољшана је инсулинска резистенција кроз смањење HOMA-IR за 1,3.Уочено је значајно смањење медијане ALT за 24,0 IU/L, AST за 9,1 IU/L и GGT за10,8 IU/L. Нежељене реакције током примене терапије су описане као благе ипролазне. Процена адхеренце извршена је Morisky скалом: у групи симплексстеатоза било је 58% адхерентних у погледу њихове хроничне терапије, док је уNASH-у висок степен адхеренце уочен код 85% пацијената. Применом SMAQскале добијени су нижи проценти адхерентних у обе групе (42,3% vs 76,2%).HUFA индекс се показао значајним за рану детекцију некроинфламације уNAFLD-у. Комбинована терапија у NASH-у је довела до побољшањабиохемијских параметара. Детектован проценат неадхерентних пацијенатаомогућава правовремену интервенцију у сврху постизања бољих исхода лечења..., The aim of doctoral dissertation was to identify parameters important to differentiate simple steatosis from NASH and to explore efficacy and safety of metformin/pentoxifylline combined treatment in NASH. Level of adherence was also evaluated. Total number of patients included in the study was 148. A proposed model named HUFA index included 4 variables (HOMA-IR, serum Uric acid, Ferritin and ALT) that were shown to be statisticaly significant. An area under receiving operating curve of 0.94 was noted for the NASH detection model, with sensitivity of 70.3%, specificity of 95.1%, positive predicitive value of 83.1% and negative predicitive value of 90.0%. Metformin and pentoxifylline were introduced in NASH cohort for 6 month, while simple steatosis cohort served as control. Decrease in median value of uric acid and calcium was observed (51μmol/L and 0.27 mmol/L, respectively). Magnesium increased for 0.11 mmol/L. Insulin resistance improved as HOMA-IR reduced for 1.3. Decrease in median value of hepatic enzymes (ALT, AST, GGT) was detected: 24.0 IU/L, 9.1 IU/L and 10.8 IU/L, respectively. Adverse drug reaction that emerged were described as mild and transient. Adherence was evaluated using Morisky scale. In simple steatosis group only 58% of patients were adherent to their chronic treatment, while NASH cohort showed optimal adherence in 85% of cases. When SMAQ scale was used, lower percentage of adherence was detected in both cohorts (42,3% vs  76,2%). HUFA index is important for early detection of necroinflammation in NAFLD. Studied therapy showed improvement of biochemical parameters. Identification of nonadherent patients is important for timely intervention and consequently better treatment outcomes.",
publisher = "Универзитет у Београду, Фармацеутски факултет",
journal = "Универзитет у Београду",
title = "Значај биохемијских параметара у диференцијацији нелкохолног стеатохепатитиса и процена исхода терапије и адхеренце, при примени метформина и пентоксифилина",
pages = "",
url = "https://hdl.handle.net/21.15107/rcub_nardus_17522"
}

Ćulafić, M.. (2020). Значај биохемијских параметара у диференцијацији нелкохолног стеатохепатитиса и процена исхода терапије и адхеренце, при примени метформина и пентоксифилина. in Универзитет у Београду
Универзитет у Београду, Фармацеутски факултет..
https://hdl.handle.net/21.15107/rcub_nardus_17522

Ćulafić M. Значај биохемијских параметара у диференцијацији нелкохолног стеатохепатитиса и процена исхода терапије и адхеренце, при примени метформина и пентоксифилина. in Универзитет у Београду. 2020;:null-.
https://hdl.handle.net/21.15107/rcub_nardus_17522 .

Ćulafić, Milica, "Значај биохемијских параметара у диференцијацији нелкохолног стеатохепатитиса и процена исхода терапије и адхеренце, при примени метформина и пентоксифилина" in Универзитет у Београду (2020),
https://hdl.handle.net/21.15107/rcub_nardus_17522 .

TY  - CONF
AU  - Milenković, Branislava
AU  - Roganović, Maša
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3737
AB  - Introduction: Pharmacists have a significant role in improving patient inhaler technique (HK. Reddel, et al. Eur Respir J 2008;32: 812; Alismail A, et al. Respir Care 2016;61:593). Hence, it is crucial for pharmacists to develop skills in educating patients on the correct use of inhalers.

Aims: The aim of the study was to evaluate the effectiveness of an educational intervention on the pharmacists’ inhaler technique demonstration skills.

Methods: The study was performed during the community pharmacists’ training classes in 2019. Demonstration of correct inhaler technique was performed for metered-dose (MDI), dry powder (DPI) and soft mist inhalers (SMI). All participants were instructed about correct technique and given placebo inhalers. After the demonstration, they were assessed on the use of each of these devices. The pharmacists were given a 1-point score for each step (1-preparation, 2-expiration, 3-inhalation, 4-holding breath) performed correctly.

Results: All participants (108) showed improved inhaler technique after training (3.8±0.5 points). Friedman test showed a significant difference in achieved score depending on the type of the inhaler (p<0.05) and the lowest was with MDI. After education, 29.6% of participants had a problem with coordination of dose release and inhalation using MDIs. Only 4.6% made an error in step 3 for DPIs (strong and fast inhalation). None of the participants made an error in the same step for SMI (slow and deep inhalation).

Conclusion: This method of inhaler technique training is sufficient to provide the skills to the pharmacist in educating patients about the correct use. However these results indicate that there was a difference in the ability to use different inhalers.
PB  - European Respiratory Society
C3  - European Respiratory Journal
T1  - Inhaler technique training of community pharmacists and common errors
VL  - 56
IS  - Suppl. 64
DO  - 10.1183/13993003.congress-2020.3174
ER  - 

@conference{
author = "Milenković, Branislava and Roganović, Maša and Kovačević, Milena and Ćulafić, Milica and Jovanović, Marija and Vučićević, Katarina and Vezmar-Kovačević, Sandra and Miljković, Branislava",
year = "2020",
abstract = "Introduction: Pharmacists have a significant role in improving patient inhaler technique (HK. Reddel, et al. Eur Respir J 2008;32: 812; Alismail A, et al. Respir Care 2016;61:593). Hence, it is crucial for pharmacists to develop skills in educating patients on the correct use of inhalers.

Aims: The aim of the study was to evaluate the effectiveness of an educational intervention on the pharmacists’ inhaler technique demonstration skills.

Methods: The study was performed during the community pharmacists’ training classes in 2019. Demonstration of correct inhaler technique was performed for metered-dose (MDI), dry powder (DPI) and soft mist inhalers (SMI). All participants were instructed about correct technique and given placebo inhalers. After the demonstration, they were assessed on the use of each of these devices. The pharmacists were given a 1-point score for each step (1-preparation, 2-expiration, 3-inhalation, 4-holding breath) performed correctly.

Results: All participants (108) showed improved inhaler technique after training (3.8±0.5 points). Friedman test showed a significant difference in achieved score depending on the type of the inhaler (p<0.05) and the lowest was with MDI. After education, 29.6% of participants had a problem with coordination of dose release and inhalation using MDIs. Only 4.6% made an error in step 3 for DPIs (strong and fast inhalation). None of the participants made an error in the same step for SMI (slow and deep inhalation).

Conclusion: This method of inhaler technique training is sufficient to provide the skills to the pharmacist in educating patients about the correct use. However these results indicate that there was a difference in the ability to use different inhalers.",
publisher = "European Respiratory Society",
journal = "European Respiratory Journal",
title = "Inhaler technique training of community pharmacists and common errors",
volume = "56",
number = "Suppl. 64",
doi = "10.1183/13993003.congress-2020.3174"
}

Milenković, B., Roganović, M., Kovačević, M., Ćulafić, M., Jovanović, M., Vučićević, K., Vezmar-Kovačević, S.,& Miljković, B.. (2020). Inhaler technique training of community pharmacists and common errors. in European Respiratory Journal
European Respiratory Society., 56(Suppl. 64).
https://doi.org/10.1183/13993003.congress-2020.3174

Milenković B, Roganović M, Kovačević M, Ćulafić M, Jovanović M, Vučićević K, Vezmar-Kovačević S, Miljković B. Inhaler technique training of community pharmacists and common errors. in European Respiratory Journal. 2020;56(Suppl. 64).
doi:10.1183/13993003.congress-2020.3174 .

Milenković, Branislava, Roganović, Maša, Kovačević, Milena, Ćulafić, Milica, Jovanović, Marija, Vučićević, Katarina, Vezmar-Kovačević, Sandra, Miljković, Branislava, "Inhaler technique training of community pharmacists and common errors" in European Respiratory Journal, 56, no. Suppl. 64 (2020),
https://doi.org/10.1183/13993003.congress-2020.3174 . .

TY  - JOUR
AU  - Ćulafić, Milica
AU  - Vezmar-Kovačević, Sandra
AU  - Dopsaj, Violeta
AU  - Oluić, Branislav
AU  - Bidžić, Nemanja
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3625
AB  - Background:The progression of the nonalcoholic fatty liver disease to nonalcoholic steatohepatitis (NASH) is multifactorial, and there is still a lack of approved medications for its  treatment.  The  study  aimed  to  evaluate  the  impact  of combined treatment with Pentoxifylline and Metformin on biochemical  parameters  in  patients  with  NASH.  Setting:Outpatient hepatology clinic.Methods:A  prospective  trial  was  conducted.  The  first cohort  included  patients  with  biopsy-proven  NASH,  while the  second  cohort  consisted  of  patients  with  biopsy-confirmed NAFLD. Blood tests were checked at baseline and every three months. Pentoxifylline at a dosage of 400 mgt.i.d.  and  Metformin  at  the  dosage  of  500  mg  t.i.d.  were introduced for six months in NASH group.  The impact of the  treatment  was  assessed  based  on  biochemical  results after combined treatment with low-cost medications. Results:All  33  NASH  patients  completed  24  weeks  of treatment. We observed significant improvement (p<0.05)of median values after treatment for the following parameters: serum uric acid levels decreased by 51.0 mmol/L, calcium decreased for 0.27 mmoL/L, magnesium showed an increase of 0.11 mmoL/L. Insulin resistance improved as a reduction of HOMA – IR by 1.3 was detected. A significant decrease of median in liver enzymes, alanine aminotransferase,  aspartate  aminotransferase  and  gamma-glutamyltransferase  by  24.0  U/L,  9.1  U/L,  10.8  U/L  respectively,was noted. Conclusions:Pentoxifylline  and  Metformin  may  provide possible  treatment  option  in  NASH.  Some  new  potential benefit  of  the  therapy  in  improving  liver  function  whilst decreasing cardiovascular risk was perceived.
AB  - Uvod: Progresija nealkoholne masne bolesti jetre (NAFLD) do nealkoholnog steatohepatitisa (NASH) je multifaktorijalna, i još uvek ne postoje zvanično odobreni lekovi za terapiju. U studiji je procenjivan uticaj kombinovane terapije pentoksifilinom i metforminom na biohemijske parametre kod pacijenata sa NASHom. Okruženje: Hepatološka ambulanta klinike. Metode: Studija je bila prospektivnog karaktera. Prva grupa uključila je pacijente sa biopsijom potvrđenim NASHom, dok su drugu grupu činili pacijenti sa biopsijom potvrđenom NAFLDom. Analize krvi vršene su svaka tri meseca. Uvedena je kombinovana terapija pentoksifilinom u dozi od 400 mg 3×1 i metforminom u dozi od 500 mg 3×1, u trajanju od šest meseci za Nash grupu. Efekat lečenja procenjen je na osnovu biohemijskih parametara nakon terapije ovim medikamentima sa niskom cenom. Rezultati: Svih 33 pacijenta su završila 24 nedelje terapije. Uočeno je značajno poboljšanje (p<0,05) vrednosti medijane za sledeće parametre: nivoi mokraćne kiseline u serumu su se snizili za 51,0 mmol/L, kalcijum je snižen za 0,27 mmol/L, magnezijum je pokazao porast za 0,11 mmol/L. Poboljšana je insulinska rezistencija konstatovana kroz smanjenje HOMA-IR za 1,3. Zabeleženo je značajno smanjenje medijane enzima jetre: alanin aminotransferaze za 24,0 U/L, aspartat aminotransferaze za 9,1 U/L i gama glutamiltransferaze za 10,8 U/L. Zaključak: Pentoksifilin sa metforminom može predstavljati moguću terapijsku opciju u NASHu. Primećena je nova potencijalna korist primenjene terapije u poboljšanju funkcije jetre i smanjenju kardiovaskularnog rizika.
PB  - Beograd : Društvo medicinskih biohemičara Srbije
T2  - Journal of Medical Biochemistry
T1  - Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis
T1  - Terapija pentoksifilinom sa metforminom poboljšava biohemijske parametre u pacijenata sa nealkoholnim steatohepatitisom
VL  - 39
IS  - 3
SP  - 290
EP  - 298
DO  - 10.2478/jomb-2019-0043
ER  - 

@article{
author = "Ćulafić, Milica and Vezmar-Kovačević, Sandra and Dopsaj, Violeta and Oluić, Branislav and Bidžić, Nemanja and Miljković, Branislava and Ćulafić, Đorđe",
year = "2020",
abstract = "Background:The progression of the nonalcoholic fatty liver disease to nonalcoholic steatohepatitis (NASH) is multifactorial, and there is still a lack of approved medications for its  treatment.  The  study  aimed  to  evaluate  the  impact  of combined treatment with Pentoxifylline and Metformin on biochemical  parameters  in  patients  with  NASH.  Setting:Outpatient hepatology clinic.Methods:A  prospective  trial  was  conducted.  The  first cohort  included  patients  with  biopsy-proven  NASH,  while the  second  cohort  consisted  of  patients  with  biopsy-confirmed NAFLD. Blood tests were checked at baseline and every three months. Pentoxifylline at a dosage of 400 mgt.i.d.  and  Metformin  at  the  dosage  of  500  mg  t.i.d.  were introduced for six months in NASH group.  The impact of the  treatment  was  assessed  based  on  biochemical  results after combined treatment with low-cost medications. Results:All  33  NASH  patients  completed  24  weeks  of treatment. We observed significant improvement (p<0.05)of median values after treatment for the following parameters: serum uric acid levels decreased by 51.0 mmol/L, calcium decreased for 0.27 mmoL/L, magnesium showed an increase of 0.11 mmoL/L. Insulin resistance improved as a reduction of HOMA – IR by 1.3 was detected. A significant decrease of median in liver enzymes, alanine aminotransferase,  aspartate  aminotransferase  and  gamma-glutamyltransferase  by  24.0  U/L,  9.1  U/L,  10.8  U/L  respectively,was noted. Conclusions:Pentoxifylline  and  Metformin  may  provide possible  treatment  option  in  NASH.  Some  new  potential benefit  of  the  therapy  in  improving  liver  function  whilst decreasing cardiovascular risk was perceived., Uvod: Progresija nealkoholne masne bolesti jetre (NAFLD) do nealkoholnog steatohepatitisa (NASH) je multifaktorijalna, i još uvek ne postoje zvanično odobreni lekovi za terapiju. U studiji je procenjivan uticaj kombinovane terapije pentoksifilinom i metforminom na biohemijske parametre kod pacijenata sa NASHom. Okruženje: Hepatološka ambulanta klinike. Metode: Studija je bila prospektivnog karaktera. Prva grupa uključila je pacijente sa biopsijom potvrđenim NASHom, dok su drugu grupu činili pacijenti sa biopsijom potvrđenom NAFLDom. Analize krvi vršene su svaka tri meseca. Uvedena je kombinovana terapija pentoksifilinom u dozi od 400 mg 3×1 i metforminom u dozi od 500 mg 3×1, u trajanju od šest meseci za Nash grupu. Efekat lečenja procenjen je na osnovu biohemijskih parametara nakon terapije ovim medikamentima sa niskom cenom. Rezultati: Svih 33 pacijenta su završila 24 nedelje terapije. Uočeno je značajno poboljšanje (p<0,05) vrednosti medijane za sledeće parametre: nivoi mokraćne kiseline u serumu su se snizili za 51,0 mmol/L, kalcijum je snižen za 0,27 mmol/L, magnezijum je pokazao porast za 0,11 mmol/L. Poboljšana je insulinska rezistencija konstatovana kroz smanjenje HOMA-IR za 1,3. Zabeleženo je značajno smanjenje medijane enzima jetre: alanin aminotransferaze za 24,0 U/L, aspartat aminotransferaze za 9,1 U/L i gama glutamiltransferaze za 10,8 U/L. Zaključak: Pentoksifilin sa metforminom može predstavljati moguću terapijsku opciju u NASHu. Primećena je nova potencijalna korist primenjene terapije u poboljšanju funkcije jetre i smanjenju kardiovaskularnog rizika.",
publisher = "Beograd : Društvo medicinskih biohemičara Srbije",
journal = "Journal of Medical Biochemistry",
title = "Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis, Terapija pentoksifilinom sa metforminom poboljšava biohemijske parametre u pacijenata sa nealkoholnim steatohepatitisom",
volume = "39",
number = "3",
pages = "290-298",
doi = "10.2478/jomb-2019-0043"
}

Ćulafić, M., Vezmar-Kovačević, S., Dopsaj, V., Oluić, B., Bidžić, N., Miljković, B.,& Ćulafić, Đ.. (2020). Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. in Journal of Medical Biochemistry
Beograd : Društvo medicinskih biohemičara Srbije., 39(3), 290-298.
https://doi.org/10.2478/jomb-2019-0043

Ćulafić M, Vezmar-Kovačević S, Dopsaj V, Oluić B, Bidžić N, Miljković B, Ćulafić Đ. Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. in Journal of Medical Biochemistry. 2020;39(3):290-298.
doi:10.2478/jomb-2019-0043 .

Ćulafić, Milica, Vezmar-Kovačević, Sandra, Dopsaj, Violeta, Oluić, Branislav, Bidžić, Nemanja, Miljković, Branislava, Ćulafić, Đorđe, "Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis" in Journal of Medical Biochemistry, 39, no. 3 (2020):290-298,
https://doi.org/10.2478/jomb-2019-0043 . .

TY  - JOUR
AU  - Vlaisavljević, Željko
AU  - Janković, Slobodan
AU  - Maksimović, Nataša
AU  - Ćulafić, Milica
AU  - Štulić, Miloš
AU  - Milovanović, Tamara
AU  - Oluić, Branislav
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3559
AB  - Objective. Nurses represent the key persons in the process of organ donation, acting as intermediaries between the patient and the family of a potential donor. The aim of this study was to analyze the factors influencing the attitudes of nurses toward bequeathing and organ and tissue donation. Methods. The research was designed as a cross-sectional study from November 2013 to November 2014 and included a sample of 264 nurses employed in the health system of Serbia. Data were collected using a specific questionnaire of 18 questions referring to the information on sociodemographic characteristics and the knowledge of organ donation. Results. The investigation enrolled 264 participants, of which 78% were women. The majority of study subjects had secondary medical education (64.4%), lived in an urban area (82.6%), were married (56.4%), and were predominantly Orthodox (87.1%) with their work experience between 5 and 10 years (29.9%) and 10 to 20 years (29.5%). The average knowledge score concerning organ donation was 29.03 (SD, 2.33; range, 23-34). There was a statistically significant difference in the scores between 2 groups formed according the length of service (P < .001) and the level of education (P ¼ .019), which showed the strongest influence on nurses’ attitudes toward donation. Conclusion. This investigation showed that nurses did not express strong positive attitude toward this issue. Further education of nurses in the Serbian health care system focusing on transplantation and bequeathing of organs and tissues are warranted. N
PB  - Elsevier USA
T2  - Transplantation Proceedings
T1  - Attitudes of Nurses Toward Organ Donation in Serbia
VL  - 52
IS  - 3
SP  - 673
EP  - 679
DO  - 10.1016/j.transproceed.2020.01.031
ER  - 

@article{
author = "Vlaisavljević, Željko and Janković, Slobodan and Maksimović, Nataša and Ćulafić, Milica and Štulić, Miloš and Milovanović, Tamara and Oluić, Branislav",
year = "2020",
abstract = "Objective. Nurses represent the key persons in the process of organ donation, acting as intermediaries between the patient and the family of a potential donor. The aim of this study was to analyze the factors influencing the attitudes of nurses toward bequeathing and organ and tissue donation. Methods. The research was designed as a cross-sectional study from November 2013 to November 2014 and included a sample of 264 nurses employed in the health system of Serbia. Data were collected using a specific questionnaire of 18 questions referring to the information on sociodemographic characteristics and the knowledge of organ donation. Results. The investigation enrolled 264 participants, of which 78% were women. The majority of study subjects had secondary medical education (64.4%), lived in an urban area (82.6%), were married (56.4%), and were predominantly Orthodox (87.1%) with their work experience between 5 and 10 years (29.9%) and 10 to 20 years (29.5%). The average knowledge score concerning organ donation was 29.03 (SD, 2.33; range, 23-34). There was a statistically significant difference in the scores between 2 groups formed according the length of service (P < .001) and the level of education (P ¼ .019), which showed the strongest influence on nurses’ attitudes toward donation. Conclusion. This investigation showed that nurses did not express strong positive attitude toward this issue. Further education of nurses in the Serbian health care system focusing on transplantation and bequeathing of organs and tissues are warranted. N",
publisher = "Elsevier USA",
journal = "Transplantation Proceedings",
title = "Attitudes of Nurses Toward Organ Donation in Serbia",
volume = "52",
number = "3",
pages = "673-679",
doi = "10.1016/j.transproceed.2020.01.031"
}

Vlaisavljević, Ž., Janković, S., Maksimović, N., Ćulafić, M., Štulić, M., Milovanović, T.,& Oluić, B.. (2020). Attitudes of Nurses Toward Organ Donation in Serbia. in Transplantation Proceedings
Elsevier USA., 52(3), 673-679.
https://doi.org/10.1016/j.transproceed.2020.01.031

Vlaisavljević Ž, Janković S, Maksimović N, Ćulafić M, Štulić M, Milovanović T, Oluić B. Attitudes of Nurses Toward Organ Donation in Serbia. in Transplantation Proceedings. 2020;52(3):673-679.
doi:10.1016/j.transproceed.2020.01.031 .

Vlaisavljević, Željko, Janković, Slobodan, Maksimović, Nataša, Ćulafić, Milica, Štulić, Miloš, Milovanović, Tamara, Oluić, Branislav, "Attitudes of Nurses Toward Organ Donation in Serbia" in Transplantation Proceedings, 52, no. 3 (2020):673-679,
https://doi.org/10.1016/j.transproceed.2020.01.031 . .

TY  - CONF
AU  - Đorđević, Jelica
AU  - Ćulafić, Milica
AU  - Stanković, Sanja
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Oluić, Branislav
AU  - Štulić, Miloš
AU  - Miljković, Branislava
AU  - Đorđe, Ćulafić
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4743
PB  - Elsevier B.V.
C3  - Clinica Chimica Acta.
T1  - Effect of tacrolimus on serum low-density lipoprotein cholesterol levels in liver transplant patients
VL  - 493
IS  - Supplement 1
SP  - S372
EP  - S372
DO  - 10.1016/j.cca.2019.03.796
ER  - 

@conference{
author = "Đorđević, Jelica and Ćulafić, Milica and Stanković, Sanja and Kovačević, Milena and Vezmar-Kovačević, Sandra and Oluić, Branislav and Štulić, Miloš and Miljković, Branislava and Đorđe, Ćulafić",
year = "2019",
publisher = "Elsevier B.V.",
journal = "Clinica Chimica Acta.",
title = "Effect of tacrolimus on serum low-density lipoprotein cholesterol levels in liver transplant patients",
volume = "493",
number = "Supplement 1",
pages = "S372-S372",
doi = "10.1016/j.cca.2019.03.796"
}

Đorđević, J., Ćulafić, M., Stanković, S., Kovačević, M., Vezmar-Kovačević, S., Oluić, B., Štulić, M., Miljković, B.,& Đorđe, Ć.. (2019). Effect of tacrolimus on serum low-density lipoprotein cholesterol levels in liver transplant patients. in Clinica Chimica Acta.
Elsevier B.V.., 493(Supplement 1), S372-S372.
https://doi.org/10.1016/j.cca.2019.03.796

Đorđević J, Ćulafić M, Stanković S, Kovačević M, Vezmar-Kovačević S, Oluić B, Štulić M, Miljković B, Đorđe Ć. Effect of tacrolimus on serum low-density lipoprotein cholesterol levels in liver transplant patients. in Clinica Chimica Acta.. 2019;493(Supplement 1):S372-S372.
doi:10.1016/j.cca.2019.03.796 .

Đorđević, Jelica, Ćulafić, Milica, Stanković, Sanja, Kovačević, Milena, Vezmar-Kovačević, Sandra, Oluić, Branislav, Štulić, Miloš, Miljković, Branislava, Đorđe, Ćulafić, "Effect of tacrolimus on serum low-density lipoprotein cholesterol levels in liver transplant patients" in Clinica Chimica Acta., 493, no. Supplement 1 (2019):S372-S372,
https://doi.org/10.1016/j.cca.2019.03.796 . .

TY  - JOUR
AU  - Ćulafić, Milica
AU  - Vezmar-Kovačević, Sandra
AU  - Dopsaj, Violeta
AU  - Stulić, Miloš
AU  - Vlaisavljević, Željko
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3262
AB  - Background and objectives: Data suggests that nearly 30% of the general population have steatosis and up to 5% of this population develops nonalcoholic steatohepatitis (NASH). Liver biopsy is still considered to be the gold standard for the diagnosis of NASH. Great effort is being made toward the identification of sensitive diagnostic tests that do not involve invasive procedures to address a common concern in patients with the nonalcoholic fatty liver disease-whether they have NASH or simple steatosis. We aimed to investigate the independent predictors and develop a non-invasive, easy-to-perform, low-cost set of parameters that may be used in clinical practice to differentiate simple steatosis from NASH. Methods: А cross-sectional study of nonalcoholic fatty liver disease (NAFLD) patients divided into two groups: group I-simple steatosis (SS) and group II-biopsy-proven NASH. Strict inclusion criteria and stepwise analysis allowed the evaluation of a vast number of measured/estimated parameters. Results: One hundred and eleven patients were included-82 with simple steatosis and 29 with biopsy-proven NASH. The probability of NASH was the highest when homeostatic model assessment of insulin resistance (HOMA-IR) was above 2.5, uric acid above 380 µmol/L, ferritin above 100 µg/L and ALT above 45 U/L. An acronym of using first letters was created and named the HUFA index. This combined model resulted in an area under the receiver operator characteristic curve (AUROC) of 0.94, provided sensitivity, specificity, positive predictive value and a negative predictive value for NASH of 70.3%, 95.1%, 83.1% and 90.0%, respectively. Conclusion: We suggest a simple non-invasive predictive index HUFA that encompasses four easily available parameters (HOMA-IR, uric acid, ferritin and ALT) to identify patients with NASH, which may reduce the need for a liver biopsy on a routine basis in patients with NAFLD.
PB  - NLM (Medline)
T2  - Medicina (Kaunas, Lithuania)
T1  - A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests
VL  - 55
IS  - 6
DO  - 10.3390/medicina55060243
ER  - 

@article{
author = "Ćulafić, Milica and Vezmar-Kovačević, Sandra and Dopsaj, Violeta and Stulić, Miloš and Vlaisavljević, Željko and Miljković, Branislava and Ćulafić, Đorđe",
year = "2019",
abstract = "Background and objectives: Data suggests that nearly 30% of the general population have steatosis and up to 5% of this population develops nonalcoholic steatohepatitis (NASH). Liver biopsy is still considered to be the gold standard for the diagnosis of NASH. Great effort is being made toward the identification of sensitive diagnostic tests that do not involve invasive procedures to address a common concern in patients with the nonalcoholic fatty liver disease-whether they have NASH or simple steatosis. We aimed to investigate the independent predictors and develop a non-invasive, easy-to-perform, low-cost set of parameters that may be used in clinical practice to differentiate simple steatosis from NASH. Methods: А cross-sectional study of nonalcoholic fatty liver disease (NAFLD) patients divided into two groups: group I-simple steatosis (SS) and group II-biopsy-proven NASH. Strict inclusion criteria and stepwise analysis allowed the evaluation of a vast number of measured/estimated parameters. Results: One hundred and eleven patients were included-82 with simple steatosis and 29 with biopsy-proven NASH. The probability of NASH was the highest when homeostatic model assessment of insulin resistance (HOMA-IR) was above 2.5, uric acid above 380 µmol/L, ferritin above 100 µg/L and ALT above 45 U/L. An acronym of using first letters was created and named the HUFA index. This combined model resulted in an area under the receiver operator characteristic curve (AUROC) of 0.94, provided sensitivity, specificity, positive predictive value and a negative predictive value for NASH of 70.3%, 95.1%, 83.1% and 90.0%, respectively. Conclusion: We suggest a simple non-invasive predictive index HUFA that encompasses four easily available parameters (HOMA-IR, uric acid, ferritin and ALT) to identify patients with NASH, which may reduce the need for a liver biopsy on a routine basis in patients with NAFLD.",
publisher = "NLM (Medline)",
journal = "Medicina (Kaunas, Lithuania)",
title = "A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests",
volume = "55",
number = "6",
doi = "10.3390/medicina55060243"
}

Ćulafić, M., Vezmar-Kovačević, S., Dopsaj, V., Stulić, M., Vlaisavljević, Ž., Miljković, B.,& Ćulafić, Đ.. (2019). A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests. in Medicina (Kaunas, Lithuania)
NLM (Medline)., 55(6).
https://doi.org/10.3390/medicina55060243

Ćulafić M, Vezmar-Kovačević S, Dopsaj V, Stulić M, Vlaisavljević Ž, Miljković B, Ćulafić Đ. A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests. in Medicina (Kaunas, Lithuania). 2019;55(6).
doi:10.3390/medicina55060243 .

Ćulafić, Milica, Vezmar-Kovačević, Sandra, Dopsaj, Violeta, Stulić, Miloš, Vlaisavljević, Željko, Miljković, Branislava, Ćulafić, Đorđe, "A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests" in Medicina (Kaunas, Lithuania), 55, no. 6 (2019),
https://doi.org/10.3390/medicina55060243 . .

TY  - CONF
AU  - Pejić, Nina
AU  - Ćulafić, Đorđe
AU  - Stojković Lalošević, Milica
AU  - Štulić, Miloš
AU  - Ćulafić, Milica
AU  - Petrović, Nataša
AU  - Kovač, Jelena
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4830
PB  - Udruženje gastroenterologa Srbije
C3  - IV Kongres gastroenterologa Srbije, Beograd, 08 - 09. Novembar 2019 - Zbornik sažetaka
T1  - „Cocoon abdomen“ nakon transplantacije jetre prikaz slučaja
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4830
ER  - 

@conference{
author = "Pejić, Nina and Ćulafić, Đorđe and Stojković Lalošević, Milica and Štulić, Miloš and Ćulafić, Milica and Petrović, Nataša and Kovač, Jelena",
year = "2019",
publisher = "Udruženje gastroenterologa Srbije",
journal = "IV Kongres gastroenterologa Srbije, Beograd, 08 - 09. Novembar 2019 - Zbornik sažetaka",
title = "„Cocoon abdomen“ nakon transplantacije jetre prikaz slučaja",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4830"
}

Pejić, N., Ćulafić, Đ., Stojković Lalošević, M., Štulić, M., Ćulafić, M., Petrović, N.,& Kovač, J.. (2019). „Cocoon abdomen“ nakon transplantacije jetre prikaz slučaja. in IV Kongres gastroenterologa Srbije, Beograd, 08 - 09. Novembar 2019 - Zbornik sažetaka
Udruženje gastroenterologa Srbije..
https://hdl.handle.net/21.15107/rcub_farfar_4830

Pejić N, Ćulafić Đ, Stojković Lalošević M, Štulić M, Ćulafić M, Petrović N, Kovač J. „Cocoon abdomen“ nakon transplantacije jetre prikaz slučaja. in IV Kongres gastroenterologa Srbije, Beograd, 08 - 09. Novembar 2019 - Zbornik sažetaka. 2019;.
https://hdl.handle.net/21.15107/rcub_farfar_4830 .

Pejić, Nina, Ćulafić, Đorđe, Stojković Lalošević, Milica, Štulić, Miloš, Ćulafić, Milica, Petrović, Nataša, Kovač, Jelena, "„Cocoon abdomen“ nakon transplantacije jetre prikaz slučaja" in IV Kongres gastroenterologa Srbije, Beograd, 08 - 09. Novembar 2019 - Zbornik sažetaka (2019),
https://hdl.handle.net/21.15107/rcub_farfar_4830 .

TY  - JOUR
AU  - Štulić, Miloš
AU  - Ćulafić, Đorđe
AU  - Boričić, Ivan
AU  - Stojković Lalošević, Milica
AU  - Pejić, Nina
AU  - Janković, Goran
AU  - Milovanović, Tamara
AU  - Ćulafić-Vojinović, Violeta
AU  - Vlaisavljević, Željko
AU  - Ćulafić, Milica
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4827
AB  - Intrahepatic cholestasis of pregnancy (ICP) is a gestation-specific liver disorder, defined most often as the onset of pruritus, usually from the third trimester of pregnancy, associated with abnormal liver test results and/or increased total serum bile acids and spontaneous relief after delivery. The 21-year-old patient was admitted to our ward in the 11th week of pregnancy due to raised liver enzymes. The first onset of pruritus and jaundice appeared a month before hospitalization. Immunology tests and Toxoplasma gondii were negative. We excluded viral etiology, while alpha-1-antitrypsin, serum and urine copper levels, and thyroid hormones were within the reference values. The patient denied she had taken any medicines and herbal preparations before and during pregnancy. Total bile acids in the serum were significantly elevated (242 μmol/L). The abdominal ultrasound revealed a regular finding. Liver biopsy suggested a cholestatic liver disorder. After a presentation of all risks, the patient decided to stop the pregnancy. After a month, the hepatogram was within the reference values. Very rarely an ICP can occur in early pregnancy (first trimester), which calls for close monitoring. The risk of serious adverse fetal outcomes and spontaneous preterm delivery is proportional with increased levels of maternal serum bile acid.
PB  - MDPI
T2  - Medicina
T1  - Intrahepatic Cholestasis of Pregnancy: A Case Study of the Rare Onset in the First Trimester
VL  - 55
IS  - 8
DO  - 10.3390/medicina55080454
ER  - 

@article{
author = "Štulić, Miloš and Ćulafić, Đorđe and Boričić, Ivan and Stojković Lalošević, Milica and Pejić, Nina and Janković, Goran and Milovanović, Tamara and Ćulafić-Vojinović, Violeta and Vlaisavljević, Željko and Ćulafić, Milica",
year = "2019",
abstract = "Intrahepatic cholestasis of pregnancy (ICP) is a gestation-specific liver disorder, defined most often as the onset of pruritus, usually from the third trimester of pregnancy, associated with abnormal liver test results and/or increased total serum bile acids and spontaneous relief after delivery. The 21-year-old patient was admitted to our ward in the 11th week of pregnancy due to raised liver enzymes. The first onset of pruritus and jaundice appeared a month before hospitalization. Immunology tests and Toxoplasma gondii were negative. We excluded viral etiology, while alpha-1-antitrypsin, serum and urine copper levels, and thyroid hormones were within the reference values. The patient denied she had taken any medicines and herbal preparations before and during pregnancy. Total bile acids in the serum were significantly elevated (242 μmol/L). The abdominal ultrasound revealed a regular finding. Liver biopsy suggested a cholestatic liver disorder. After a presentation of all risks, the patient decided to stop the pregnancy. After a month, the hepatogram was within the reference values. Very rarely an ICP can occur in early pregnancy (first trimester), which calls for close monitoring. The risk of serious adverse fetal outcomes and spontaneous preterm delivery is proportional with increased levels of maternal serum bile acid.",
publisher = "MDPI",
journal = "Medicina",
title = "Intrahepatic Cholestasis of Pregnancy: A Case Study of the Rare Onset in the First Trimester",
volume = "55",
number = "8",
doi = "10.3390/medicina55080454"
}

Štulić, M., Ćulafić, Đ., Boričić, I., Stojković Lalošević, M., Pejić, N., Janković, G., Milovanović, T., Ćulafić-Vojinović, V., Vlaisavljević, Ž.,& Ćulafić, M.. (2019). Intrahepatic Cholestasis of Pregnancy: A Case Study of the Rare Onset in the First Trimester. in Medicina
MDPI., 55(8).
https://doi.org/10.3390/medicina55080454

Štulić M, Ćulafić Đ, Boričić I, Stojković Lalošević M, Pejić N, Janković G, Milovanović T, Ćulafić-Vojinović V, Vlaisavljević Ž, Ćulafić M. Intrahepatic Cholestasis of Pregnancy: A Case Study of the Rare Onset in the First Trimester. in Medicina. 2019;55(8).
doi:10.3390/medicina55080454 .

Štulić, Miloš, Ćulafić, Đorđe, Boričić, Ivan, Stojković Lalošević, Milica, Pejić, Nina, Janković, Goran, Milovanović, Tamara, Ćulafić-Vojinović, Violeta, Vlaisavljević, Željko, Ćulafić, Milica, "Intrahepatic Cholestasis of Pregnancy: A Case Study of the Rare Onset in the First Trimester" in Medicina, 55, no. 8 (2019),
https://doi.org/10.3390/medicina55080454 . .

TY  - CONF
AU  - Kovačević, Milena
AU  - Ćulafić, Milica
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4745
AB  - Prema podacima Svetske zdravstvene organizacije, dijabetes melitus ubraja se među četiri najčešće hronične nezarazne bolesti, Procenjuje se da u svetu boluje 422 miliona ljudi, sa prevalencom od 8,5%, što odgovara populaciji evropskog kontinenta. Broj obolelih od dijabetesa pokazuje trend rasta i poprima razmere globalne epidemije. Značajni troškovi koji se generišu u zdravstvenim sistemima takođe pokazuju tendenciju porasta Pacijenti sa dijabetesom imaju dva puta veći rizik da dožive moždani udar u određenim starosnim grupama; dijabetes je vodeći uzrok nastanka hronične bolesti bubrega; među vodećim je uzrocima oštećenja vida i slepila u razvijenim zemljama; amputacija donjih ekstremiteta je deset puta češća među pacijentima sa dijabetesom; rizik od tuberkuloze tri puta veći u ovoj populaciji. Pacijenti sa dijabetesom zahtevaju 2-3 puta veće izdvajanje resursa u zdravstvenom sistemu, nego što je to slučaj sa pacijentima bez ove bolesti, koje može iznositi do 15% ukupnog budžeta fonda za zdravstveno osiguranje. Zbog starenja populacije, najveći porast navedenih troškova očekuje se u zemljama sa niskim i srednjim dohotkom. Pacijenti sa dijabetesom najčešće se zbrinjavaju u ustanovama sekundarnog i tercijarnog nivoa zdravstvene zaštite, i to kada se pojavio neki akutni događaj ili su se već razvile komplikacije bolesti. Kako bi se omogućila rana detekcija i pravovremena terapija, zbrinjavanje hroničnih nezaraznih bolesti treba ojačati i integrisati u primarnu zdravstvenu zaštitu. Centralnu strategiju prepoznatu na svetskom nivou predstavlja proširenje paketa usluga primarne zdravstvene zaštite koje bi uključile ključne intervencije za zbrinjavanje ovih pacijenata. U zemljama sa niskim i srednjim dohotkom, kojima pripadaju i države Balkana, najbolja troškovna efektivnost i izvodljivost dokazana je za sledeće intervencije: kontrola krvnog pritiska, kontrola glikemije i nega stopala.” U zemljama regiona opterećenje dijabetesom je značajno: svrstan je među prvih pet vodećih uzroka smrti u ukupnoj populaciji, i u svim zemljama prati rastući trend. Zbog toga je usvojena Strategija za prevenciju i kontrolu hroničnih nezaraznih bolesti, koja je uvrstila dijabetes kao jedan od pet zdravstvenih problema u fokusu. Kao dokument od nacionalnog značaja, strategija je posvećena unapređenju zdravlja stanovništva, kroz smanjenje obolevanja i umiranja, poboljšanja kvaliteta života i smanjenja invalidnosti. Strategija, odnosno Akcioni plan za prevenciju i kontrolu hroničnih nezaraznih bolesti, usvojeni su u svim zemljama regiona: u Republici Srpskoj (2003.), Crnoj Gori (2008.), Srbiji (2009.), Hrvatskoj (akcioni plan za period 2015-2020), i Federaciji Bosne i Hercegovine (akcioni plan za period 2019.-2025.). U Hrvatskoj je dijabetes 4. Vodeći uzrok smrti (što čini 4,4%), gde je evidentiran broj od preko 304 000 pacijenata u Registru osoba sa šećernom bolešću. U Federaciji Bosne i Hercegovine, endokrina i metabolička oboljenja sa poremećajima u ishrani rangirana su takođe kao 4. Vodeći uzrok smrti (6%). Prema evidenciji na osnovu ambulantno-polikliničkih podataka, registrovano je 76.808 slučajeva dijabetesa, što je rastući trend, ali se smatra nizom procenom od realne situacije. Tačni podaci o broju obolelih u Federaciji Bosne i Hercegovine ne postoje, pošto još uvek nije uspostavljen registar za dijabetes. U primarnoj zdravstvenoj zaštiti u Crnoj Gori registrovano je 23.278 poseta zbog dijabetesa u 2016. Godini. Sa procenjenom prevalencom dijabetesa od 12% na osnovu nacionalnog registra, Crna Gora svrstana je u sam evropski vrh po broju oboljevanja. Prema proceni Instituta za javno zdravlje Srbije i Registra za dijabetes, od dijabetesa boluje približno 600.000 osoba ili 8,5% odraslog stanovništva, dok je rangiran kao treći vodeći uzrok smrtnosti u Republici Srbiji. Što se tiče Republike Srpske, podaci o obolevanju prate se putem prijava od strane lekara primarne zdravstvene zaštite. Procenjena prevalenca od 5,2% u 2017. Godini smatra se da je niža od realne (6-8%), i posledica je tadašnje nepotpune instalacije softvera za unos podataka u Registar obolelih. Rezultati istraživanja u primarnoj zdravstvenoj zaštiti ukazuju na neadekvatnu kontrolu glikemije i drugih kardiovaskularnih faktora rizika u populaciji dijabetičara: ciljna vrednost glikoziliranog hemoglobina (HbAic) postignuta je tek kod 50% pacijenata, kontrola lipida takođe kod oko 50% pacijenata, dok 50-62% pacijenata nisu dostigli ciljnu vrednost krvnog pritiska (1012) Štaviše, tek je 13% pacijenata dostiglo željenu vrednost sva tri parametra (HbAs, lipidni profil i krvni pritisak) [12] Veoma značajan faktor koji doprinosi suboptimalnim ishodima terapije jeste nizak stepen adherence. Zadovoljavajući stepen adherence prema lekovima za kontrolu glikemije (definisan kao ≥ 80%) pokazan je kod 38,5-93,1% pacijenata. Iznos participacije, prisustvo depresije, i primena lekova više od dva puta dnevno identifikovani su kao značajni prediktori niskog stepena adherence. Veći broj studija potvrdio je povezanost visokog stepena adherence sa boljom kontrolom dijabetesa, manjim brojem hospitalizacija i nižim troškovima.(14) Procenjuje se da oko 85% pacijenata preuzme u apoteci prvi put propisan lek za kontrolu dijabetesa, a procenat je čak i manji za insulin, nego za oralne antidijabetike. Drugi značajan problem je perzistencija, jer je pokazano da oko 50% pacijenata samoinicijativno smanji dozu ili prestane sa primenom leka nakon prve godine. Specifičnost preparata insulina i nepoznavanje njihovog načina primene osnovni je uzrok problema sa niskim stepenom adherence i perzistencije. Podaci iz regiona potvrđuju navedene rezultate. Prema podacima iz Registra, u Hrvatskoj je regulacija glikemije bila dobra (HbA <6,5%) kod samo 33% bolesnika. Zbog toga je u cilju unapređenja ishoda terapije, u Nacionalnom programu istaknuta uloga farmaceuta kao najdostupnijeg zdravstvenog radnika u brojnim aktivnostima usmerenim ka edukaciji opšte populacije i populacije sa šećernom bolešću, učestvovanje u timovima primarne, sekundarne i tercijarne zdravstvene zaštite, rano otkrivanje šećerne bolesti u opštoj populaciji i kod trudnica, kao i u daljoj edukaciji kadrova zdravstvenih profesionalaca Podaci iz istraživanja primarne zdravstvene zaštite u Srbiji takođe pokazuju nedovoljnu efikasnost terapije dijabetesa i nizak stepen adherence. Kako bi se postiglo sveobuhvatno i ujednačeno unapređenje kvaliteta farmaceutske zdravstvene zaštite (FZZ), izrađene su Smernice za farmaceute čiji je osnovni cilj da se sistematizuje i standardizuje pružanje usluge pacijentima sa dijabetesom, koju čini određeni set informacija. Na osnovu dostupnog materijala u okviru tri smernice: (1) FZZ u primeni pen-insulinske terapije, (2) FZZ pacijenata sa dijabetesom – savetovanje o nefarmakološkim merama, 1 (3) FZZ pacijenata sa dijabetesom prevencija komplikacija, farmaceut može da kreira materijal za savetovanje prilagođen potrebama individualnog pacijenta, kroz formiranje ček-liste i planiranje učestalosti, odnosno periodičnosti savetovanja.
PB  - Farmaceutsko društvo Republike Srpske
C3  - XXII Simpozijum farmaceuta Republike Srpske sa međunarodnim učešćem, Zbornik radova
T1  - Farmaceutska zdravstvena zaštita u terapiji dijabetesa
SP  - 26
EP  - 28
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4745
ER  - 

@conference{
author = "Kovačević, Milena and Ćulafić, Milica",
year = "2019",
abstract = "Prema podacima Svetske zdravstvene organizacije, dijabetes melitus ubraja se među četiri najčešće hronične nezarazne bolesti, Procenjuje se da u svetu boluje 422 miliona ljudi, sa prevalencom od 8,5%, što odgovara populaciji evropskog kontinenta. Broj obolelih od dijabetesa pokazuje trend rasta i poprima razmere globalne epidemije. Značajni troškovi koji se generišu u zdravstvenim sistemima takođe pokazuju tendenciju porasta Pacijenti sa dijabetesom imaju dva puta veći rizik da dožive moždani udar u određenim starosnim grupama; dijabetes je vodeći uzrok nastanka hronične bolesti bubrega; među vodećim je uzrocima oštećenja vida i slepila u razvijenim zemljama; amputacija donjih ekstremiteta je deset puta češća među pacijentima sa dijabetesom; rizik od tuberkuloze tri puta veći u ovoj populaciji. Pacijenti sa dijabetesom zahtevaju 2-3 puta veće izdvajanje resursa u zdravstvenom sistemu, nego što je to slučaj sa pacijentima bez ove bolesti, koje može iznositi do 15% ukupnog budžeta fonda za zdravstveno osiguranje. Zbog starenja populacije, najveći porast navedenih troškova očekuje se u zemljama sa niskim i srednjim dohotkom. Pacijenti sa dijabetesom najčešće se zbrinjavaju u ustanovama sekundarnog i tercijarnog nivoa zdravstvene zaštite, i to kada se pojavio neki akutni događaj ili su se već razvile komplikacije bolesti. Kako bi se omogućila rana detekcija i pravovremena terapija, zbrinjavanje hroničnih nezaraznih bolesti treba ojačati i integrisati u primarnu zdravstvenu zaštitu. Centralnu strategiju prepoznatu na svetskom nivou predstavlja proširenje paketa usluga primarne zdravstvene zaštite koje bi uključile ključne intervencije za zbrinjavanje ovih pacijenata. U zemljama sa niskim i srednjim dohotkom, kojima pripadaju i države Balkana, najbolja troškovna efektivnost i izvodljivost dokazana je za sledeće intervencije: kontrola krvnog pritiska, kontrola glikemije i nega stopala.” U zemljama regiona opterećenje dijabetesom je značajno: svrstan je među prvih pet vodećih uzroka smrti u ukupnoj populaciji, i u svim zemljama prati rastući trend. Zbog toga je usvojena Strategija za prevenciju i kontrolu hroničnih nezaraznih bolesti, koja je uvrstila dijabetes kao jedan od pet zdravstvenih problema u fokusu. Kao dokument od nacionalnog značaja, strategija je posvećena unapređenju zdravlja stanovništva, kroz smanjenje obolevanja i umiranja, poboljšanja kvaliteta života i smanjenja invalidnosti. Strategija, odnosno Akcioni plan za prevenciju i kontrolu hroničnih nezaraznih bolesti, usvojeni su u svim zemljama regiona: u Republici Srpskoj (2003.), Crnoj Gori (2008.), Srbiji (2009.), Hrvatskoj (akcioni plan za period 2015-2020), i Federaciji Bosne i Hercegovine (akcioni plan za period 2019.-2025.). U Hrvatskoj je dijabetes 4. Vodeći uzrok smrti (što čini 4,4%), gde je evidentiran broj od preko 304 000 pacijenata u Registru osoba sa šećernom bolešću. U Federaciji Bosne i Hercegovine, endokrina i metabolička oboljenja sa poremećajima u ishrani rangirana su takođe kao 4. Vodeći uzrok smrti (6%). Prema evidenciji na osnovu ambulantno-polikliničkih podataka, registrovano je 76.808 slučajeva dijabetesa, što je rastući trend, ali se smatra nizom procenom od realne situacije. Tačni podaci o broju obolelih u Federaciji Bosne i Hercegovine ne postoje, pošto još uvek nije uspostavljen registar za dijabetes. U primarnoj zdravstvenoj zaštiti u Crnoj Gori registrovano je 23.278 poseta zbog dijabetesa u 2016. Godini. Sa procenjenom prevalencom dijabetesa od 12% na osnovu nacionalnog registra, Crna Gora svrstana je u sam evropski vrh po broju oboljevanja. Prema proceni Instituta za javno zdravlje Srbije i Registra za dijabetes, od dijabetesa boluje približno 600.000 osoba ili 8,5% odraslog stanovništva, dok je rangiran kao treći vodeći uzrok smrtnosti u Republici Srbiji. Što se tiče Republike Srpske, podaci o obolevanju prate se putem prijava od strane lekara primarne zdravstvene zaštite. Procenjena prevalenca od 5,2% u 2017. Godini smatra se da je niža od realne (6-8%), i posledica je tadašnje nepotpune instalacije softvera za unos podataka u Registar obolelih. Rezultati istraživanja u primarnoj zdravstvenoj zaštiti ukazuju na neadekvatnu kontrolu glikemije i drugih kardiovaskularnih faktora rizika u populaciji dijabetičara: ciljna vrednost glikoziliranog hemoglobina (HbAic) postignuta je tek kod 50% pacijenata, kontrola lipida takođe kod oko 50% pacijenata, dok 50-62% pacijenata nisu dostigli ciljnu vrednost krvnog pritiska (1012) Štaviše, tek je 13% pacijenata dostiglo željenu vrednost sva tri parametra (HbAs, lipidni profil i krvni pritisak) [12] Veoma značajan faktor koji doprinosi suboptimalnim ishodima terapije jeste nizak stepen adherence. Zadovoljavajući stepen adherence prema lekovima za kontrolu glikemije (definisan kao ≥ 80%) pokazan je kod 38,5-93,1% pacijenata. Iznos participacije, prisustvo depresije, i primena lekova više od dva puta dnevno identifikovani su kao značajni prediktori niskog stepena adherence. Veći broj studija potvrdio je povezanost visokog stepena adherence sa boljom kontrolom dijabetesa, manjim brojem hospitalizacija i nižim troškovima.(14) Procenjuje se da oko 85% pacijenata preuzme u apoteci prvi put propisan lek za kontrolu dijabetesa, a procenat je čak i manji za insulin, nego za oralne antidijabetike. Drugi značajan problem je perzistencija, jer je pokazano da oko 50% pacijenata samoinicijativno smanji dozu ili prestane sa primenom leka nakon prve godine. Specifičnost preparata insulina i nepoznavanje njihovog načina primene osnovni je uzrok problema sa niskim stepenom adherence i perzistencije. Podaci iz regiona potvrđuju navedene rezultate. Prema podacima iz Registra, u Hrvatskoj je regulacija glikemije bila dobra (HbA <6,5%) kod samo 33% bolesnika. Zbog toga je u cilju unapređenja ishoda terapije, u Nacionalnom programu istaknuta uloga farmaceuta kao najdostupnijeg zdravstvenog radnika u brojnim aktivnostima usmerenim ka edukaciji opšte populacije i populacije sa šećernom bolešću, učestvovanje u timovima primarne, sekundarne i tercijarne zdravstvene zaštite, rano otkrivanje šećerne bolesti u opštoj populaciji i kod trudnica, kao i u daljoj edukaciji kadrova zdravstvenih profesionalaca Podaci iz istraživanja primarne zdravstvene zaštite u Srbiji takođe pokazuju nedovoljnu efikasnost terapije dijabetesa i nizak stepen adherence. Kako bi se postiglo sveobuhvatno i ujednačeno unapređenje kvaliteta farmaceutske zdravstvene zaštite (FZZ), izrađene su Smernice za farmaceute čiji je osnovni cilj da se sistematizuje i standardizuje pružanje usluge pacijentima sa dijabetesom, koju čini određeni set informacija. Na osnovu dostupnog materijala u okviru tri smernice: (1) FZZ u primeni pen-insulinske terapije, (2) FZZ pacijenata sa dijabetesom – savetovanje o nefarmakološkim merama, 1 (3) FZZ pacijenata sa dijabetesom prevencija komplikacija, farmaceut može da kreira materijal za savetovanje prilagođen potrebama individualnog pacijenta, kroz formiranje ček-liste i planiranje učestalosti, odnosno periodičnosti savetovanja.",
publisher = "Farmaceutsko društvo Republike Srpske",
journal = "XXII Simpozijum farmaceuta Republike Srpske sa međunarodnim učešćem, Zbornik radova",
title = "Farmaceutska zdravstvena zaštita u terapiji dijabetesa",
pages = "26-28",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4745"
}

Kovačević, M.,& Ćulafić, M.. (2019). Farmaceutska zdravstvena zaštita u terapiji dijabetesa. in XXII Simpozijum farmaceuta Republike Srpske sa međunarodnim učešćem, Zbornik radova
Farmaceutsko društvo Republike Srpske., 26-28.
https://hdl.handle.net/21.15107/rcub_farfar_4745

Kovačević M, Ćulafić M. Farmaceutska zdravstvena zaštita u terapiji dijabetesa. in XXII Simpozijum farmaceuta Republike Srpske sa međunarodnim učešćem, Zbornik radova. 2019;:26-28.
https://hdl.handle.net/21.15107/rcub_farfar_4745 .

Kovačević, Milena, Ćulafić, Milica, "Farmaceutska zdravstvena zaštita u terapiji dijabetesa" in XXII Simpozijum farmaceuta Republike Srpske sa međunarodnim učešćem, Zbornik radova (2019):26-28,
https://hdl.handle.net/21.15107/rcub_farfar_4745 .